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Abstract 
Many organisms have evolved DNA damage response mechanisms to deal with the 
constant damage to DNA caused by endogenous and exogenous agents. These mechanisms 
activate cell cycle checkpoints to allow time for DNA repair or, in the case of severely damaged 
DNA, initiate cell death mechanisms to maintain genomic integrity. The cell’s response to DNA 
damaging agents includes wide spread changes in the transcriptional state of the cell that have 
been implicated in cell death or survival decisions. However, we do not fully understand how the 
multiple and sometimes opposing transcriptional signals are interpreted to make these critical 
decisions. A computational and systems biology approach was taken to study the wide-spread 
transcriptional changes induced in human cell lines after exposure to a DNA damaging and 
chemotherapeutic agent, 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU or carmustine). 
Cell lines with extreme sensitivity or resistance to BCNU were identified from a set of 
twenty four genetically diverse human lymphoblastoid cell lines using a high-throughput method 
that was developed as part of this thesis. This assay has broad applications and can be used to 
simultaneously screen multiple cell lines and drugs for accurate measurements of cell 
proliferation and survival after drug treatment. The assay has the advantage of having a large 
dynamic range that allows sensitivity measurements on a multi-log scale allowing better 
resolution of comparative sensitivities.  
Temporal transcription profiles were measured in cell lines with extreme BCNU 
sensitivity or resistance to generate a large transcription data set amenable to bioinformatics 
analysis. A transcriptional signature of 706 genes, differentially expressed between BCNU 
sensitive and resistant cell lines, was identified. Network and gene ontology enrichment 
identified these differentially expressed genes as being involved in key DNA damage response 
processes like apoptosis and mitosis. Experimental evidence showed that the transcription 
signature correlated with observed cellular phenotypes. Furthermore, the NF-Y transcription 
factor binding motif was enriched in the promoter region of 62 mitosis-related genes down-
regulated in BCNU sensitive but not resistant cell lines. Chromatin immunoprecipitation 
followed by sequencing (ChIP-seq) confirmed NF-Y occupancy in 54 of the 62 genes, thus 
implicating NF-Y as a possible regulator of the observed stalling of entry into mitosis.  
Using experimental and computational techniques we deciphered the functional 
importance of differential transcription between BCNU sensitive and resistant cell lines and 
identified NF-Y as an important factor in the transcriptional and phenotypic cell response to 
BCNU such as the control of entry into mitosis. 
 
Thesis Advisor: Leona Samson 
Title:  Director, Center for Environmental Health Sciences 
          Uncas and Helen Whitaker Professor of Biological Engineering and Biology 
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1.1  DNA damage and maintenance of genomic integrity 
 
1.1.1 The importance of DNA repair 
 
DNA damaging agents are ubiquitous in our environment and within our bodies. Every day, 
these endogenous and exogenous DNA damaging agents generate up to 105 DNA lesions per cell 
in our bodies (1). Unrepaired DNA lesions pose a serious threat to our health since they lead to 
mutations or premature cell death which could exacerbate life-threatening diseases like cancer 
(2), neurodegenerative disease (3,4) and premature aging (5-7). Because of the harmful 
consequences of unrepaired DNA lesions, we have evolved DNA repair and damage response 
mechanisms that get rid of damaged DNA, thus maintaining genomic integrity and preventing 
disease (8,9).  
 
The DNA damaging agents we are exposed to are of many different kinds. They include 
radiation from medical x-rays, UV from sunlight, chemical pollutants in the air we breathe, the 
food we eat and fluids we drink (10). In addition to these external agents, there are endogenous 
sources of DNA damage including nucleotide misincorporation during DNA replication, 
chemical instability of DNA (11,12) and most importantly internal processes like metabolism 
and the inflammatory response which generates reactive oxygen species that are extremely 
detrimental to DNA (13-15). These different sources of DNA damage generate various kinds of 
DNA lesions such as mismatches, small or bulky base adducts, single or double stranded breaks 
and intra- or inter-strand crosslinks.  
 
To deal with the multitude of lesions seen by a cell at any given point in time, we have numerous 
types of repair mechanisms. Mismatches are detected by the mismatch repair complexes 
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followed by a single-strand incision that is then repaired and sealed by nucleases, polymerases 
and ligases (16).  Small adducts can be removed by direct reversal proteins like O6- 
methylgaunine methyl transferase (MGMT) and the alkB homolog (ALKBH) proteins. Other 
small lesions such as small alkylated or oxidaized base lesions are generally removed by base 
excision repair where the base lesion is detected by a DNA glycosylase and removed. DNA is 
nicked at the resulting abasic site, followed by processing at the 5’ and 3’ ends which allows the 
filling and ligation of DNA (17,18). DNA distorting lesions and intrastrand lesions, such as 
pyrimidine dimers generated by UV, are removed by nucleotide excision repair (19), while inter-
strand crosslinks such as those generated by many chemotherapeutics are repaired by the 
Fanconi anemia proteins, nucleotide excision repair proteins and homologous recombination 
proteins (19,20). Double strand breaks generated by radiation or as an intermediate during the 
processing of other lesions can be repaired by non-homologous end joining or homologous 
recombination (21-23). There are also translesion polymerases that can replicate DNA past 
certain poorly repaired lesions thus allowing cell survival but increasing mutation rates (24-26). 
 
Though DNA repair is vital in maintaining genomic integrity, it does not work in isolation. In 
fact, there is a whole array of processes initiated after DNA damage to work in concert with 
repair mechanisms to ensure proper restoration and recovery of the cell after DNA damage. 
These processes are collectively termed as DNA damage response (DDR) mechanisms. 
 
1.1.2 DNA damage response mechanisms 
 
Following the detection of DNA damage, there are key DDR mechanisms initiated in our cells 
that amplify the DNA damage signal, recruit DNA repair proteins and trigger multiple 
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downstream processes that facilitate repair of damaged DNA (27-29). There are two groups of 
proteins that are currently thought to be key mediators of the DNA damage response; the 
phosphoinositol-3-kinase-like kinases DNA-PK, ATM and ATR, and members of the poly-ADP-
ribose-polymerase (PARP) family, PARP1 and PARP2 (27,30,31). DNA-PK and ATM are 
activated in response to double strand breaks depending on the sensors that detect the damage 
which varies between cell types and cell cycle phase. If the heterodimer Ku70/Ku80 detects the 
double strand breaks, then DNAPK is recruited and preferentially initiates non-homologous end 
joining (32). On the other hand, if the double strand break is detected by the MRE11-RAD50-
NBS1 complex (MRN), then ATM is activated, leading to preferential activation of homologous 
recombination (33).  Single strand breaks are detected by PARP1/2 (31) whereas RPA coated 
single-stranded DNA generated during replication stress activates ATR (34,35). Once these 
mediators are activated, they in turn activate downstream proteins either by post-translational 
modifications of the targets or by recruiting other proteins to make these activating 
modifications. For example, PARP adds poly(ADP-ribose) chains to histones to initiate 
chromatin remodeling and recruitment of repair factors as well as chromatin modifiers such as 
histone deacetylases (31,36). Similarly ATM and ATR were recently shown to phosphorylate 
and modify proteins involved not only in repair, but in more general cellular processes like RNA 
splicing, metabolic signaling, cell cycle checkpoints, transcription and chromatin remodeling 
(37). All of these effects have been shown to be important for cell recovery upon exposure to 
DNA damaging agents, and the loss of any one of them results in compromised DNA repair and 
recovery. This suggests that the DNA damage response mechanisms are broad in nature and 
work hand in hand in a coordinated manner to help the cell recover from being exposed to DNA 
damaging agents (Figure 1.1). 
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Figure 1.1: The wide range of cellular processes initiated by the DNA damage response. 
 
 
 
The figure is modified from (27) to highlight the wide range of cellular processes initiated after DNA 
damage (dotted arrows), the phenotypic outcome of the cell (black boxes) and the possible organism level 
consequences of aberrant DNA damage response mechanisms (green boxes) 
Chapter 1: Introduction 
 
       
   
16 
The effects and importance of all the numerous and varied signals initiated after DNA damage 
are still not completely understood and are areas of active research. Of the numerous targets of 
ATM and ATR, CHK2 and CHK1 are the best studied so far. Once ATM and ATR are 
phosphorylated and activated, they phosphorylate CHK2 and CHK1, respectively (27,38,39). 
One of the functions of these checkpoint kinases is to phosphorylate and inactivate the Cdc25 
phosphatases (40,41). During normal cell cycle, the Cdc25 phosphatases remove the inhibitory 
phosphate on their target cyclin dependent kinases thus enabling progression through cell cycle 
(42). Therefore, when these phosphatases are inhibited by DNA damage induced CHK2 or 
CHK1 phosphorylation, cells are stalled in G1, S or G2 (43), allowing time for the repair of 
DNA lesions, and preventing replication of damaged DNA, entry into mitosis and the 
segregation of damaged chromosomes. 
 
In addition to activating cell cycle arrest, ATM and ATR also induce transcriptional changes 
through the direct or indirect activation of transcription factors such as P53, NF-κB, E2F1 and 
Sp-1 (44-47). These transcription factors induce transcriptional changes such as regulation of cell 
cycle checkpoint genes, apoptotic genes or survival genes; these transcriptional responses are 
just as critical as DNA repair mechanisms for helping cells recover from exposure to a DNA 
damaging agent.  
 
1.1.3 Cell death or survival decisions  
 
The process by which a cell decides to die in the presence of irreparable damage is extremely 
important for the maintenance of genomic integrity in multi-cellular organisms. The decision 
against death in a cell unable to repair its damaged DNA can lead to mutations or gross 
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chromosomal changes that could continue to carcinogenesis. This is often observed as the 
increased incidence of cancer in people harboring mutations in DNA repair proteins such as 
ATM, BRCA1 and the Xeroderma Pigmentosum (XP) family of proteins. On the other hand, 
premature death of cells that have slow or low levels of DNA repair leads to unwanted cell death 
and premature aging for the organism (1,27,48). Therefore proper death or survival decisions at 
the cellular level are crucial for the whole organism’s health and survival.  
 
Although we are aware of the significance of accurate cell death or survival decisions and the 
many factors that affect these decisions, we do not fully understand how they integrate in the 
context of the cell to make these critical decisions. Experimental evidence shows that cell fate 
decisions vary greatly depending on the severity of damage and the cell type (49). This could be 
due to the intricate interplay and varying efficiencies of DNA repair, cell cycle control and cell 
death initiation between different cell types. All of these processes are, at least partially, 
regulated transcriptionally by DDR transcription factors. Interestingly, many of these DDR 
transcription factors are mutated in cancer. In particular, p53 is mutated in ~50% of all tumors 
(50). Other key DDR transcription factors such as E2F1, AP-1 and NF-κB, are also linked to 
expression changes characteristic of human tumors (51-54). These observations suggest that the 
transcriptional response to DNA damage may be crucial in making correct cell death or survival 
decisions. 
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1.2 The role of transcription in cell death or survival decisions 
 
1.2.1 Transcriptional response after exposure to DNA damaging agents 
 
The prominent role of the transcriptional response to DNA damage is seen by the significant 
genome-wide transcriptional changes induced upon exposure to DNA damaging agents in yeast 
and mammalian cells, not only for genes involved in DNA damage related functions like cell 
cycle arrest and apoptosis, but also in other cellular processes such as protein degradation and 
metabolism (55-58). Moreover, in addition to the increased incidence of mutated transcription 
factors in cancer (59), the increased sensitivity to DNA damaging agents of yeast strains that 
were silenced in genes involved in transcription regulation (60,61) shows the importance of 
transcriptional control in protecting cells against DNA damaging agents. It is important to note 
that many of the DNA damaging agents used in these studies also damage other molecules in the 
cell. Therefore the transcriptional responses observed might also be important for the cell’s 
response to cell-wide damage. 
 
Some mammalian transcription factors thought to regulate these gene expression changes after 
damage include p53, E2F1, NF-κB, AP-1, FKHR, ATF and c-Myc. These are by no means the 
only transcription factors involved in the transcriptional control of the DDR but are the few that 
have been studied to some extent in the context of DNA damage response. Yet, the temporal 
activation and the co-ordination of their targets to elicit the observed phenotype are largely 
unknown. Moreover, what is known is confounding; many of these transcription factors can 
induce both anti- and pro-apoptotic genes and therefore the outcome of their transcriptional 
activation after DNA damage is not easily deducible. These transcription factors also induce or 
repress transcriptional activity of each other, further complicating the picture. 
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p53 is activated by many post-translational mechanisms including phosphorylation by ATM, 
ATR, Chk1 or Chk2. p53 phosphorylation prevents its nuclear export and degradation, and 
results in its nuclear accumulation and activation (47,62-65). Activated p53 causes G1/S arrest 
by induction of CDKN1A (p21), the product of which is an inhibitor of the cyclin dependent 
kinase (CDK)-2 (66). Activated p53 also maintains a G2/M arrest by repressing CCNB1 (cyclin 
B1) and inducing the CDK1 inhibitors GADD45A and 14-3-3σ (67). Apoptosis related genes 
such as BCL2 (anti-apoptotic) plus PUMA, NOXA and BAX (pro-apoptotic) are transactivated by 
p53. Since p53 induces both pro- and anti-apoptotic genes, the outcome of p53 activation is 
difficult to predict (68). Like p53, E2F1 has both pro- and anti-apoptotic arms that require strict 
control for normal cell function. E2F1 regulates genes required for progression into S-phase and 
is negatively regulated by pRB which is a p53 target. Targets of E2F1 include DNA repair genes 
(e.g Rad51), signal transducers (e.g ATM) and pro-apoptotic genes (e.g PUMA and NOXA) 
(69,70). E2F1 also induces an anti-apoptotic function through indirect activation of the 
PI3K/AKT survival pathway (71,72). Similar to p53 and E2F1, NF-κB is activated in response to 
DNA damage by IKK or ATM mediated phosphorylation of IκB (73). NF-κB activates anti-
apoptotic genes in most cases, though in some tissues, pro-apoptotic genes are also induced. NF-
κB has also been shown to repress p53 (74). 
 
Because these DDR transcription factors induce genes involved cell death as well as cell 
survival, the process by which cells decide between the survival arm and the death arm is 
difficult to comprehend and deduce. This decision process in the presence of two orthogonal 
signals is not yet understood, and is an area of active research. 
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1.2.2 The possible role of transcriptional kinetics in cell death or survival 
mechanisms 
 
The transcriptional response to DNA damage is inherently dynamic because of the kinetics 
implicit in upstream signaling, varying rates of mRNA transcription and translation as well as the 
cross-regulation and feed-back loops within transcriptional networks. Moreover, as DNA repair 
progresses, the initiating signal - the amount and extent of DNA damage - also changes 
dynamically thus altering downstream transcription control. 
 
Because of the dynamic nature of the transcriptional response to DNA damage, the kinetics of 
transcription might play an important role in the phenotypic outcome of the cell. For example, 
the strength of induction of anti- and pro-apoptotic genes may differ, thus enabling one of the 
processes to win out over the other as time progresses. Similarly, there might be a difference in 
transcription rates or mRNA degradation rates for genes involved in the two opposing arms of 
the cell decision process.  Additionally, the level of transcription factor activation may vary 
depending upon the severity of the damage present, which, in the presence of active DNA repair, 
will also change over time. This could confer different transcript induction patterns at different 
times post DNA damage, thus influencing the cell death/survival decision in the cell. 
 
Temporal transcription patterns could also play a role in keeping track of the time elapsed since 
damage, an important aspect in the decision between continued cell cycle arrest or cell death. For 
example if DNA damage persisted for a long time, the continued induction of apoptotic genes or 
continued repression of anti-apoptotic genes, could drive the cell to induce cell death. 
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1.3 Studying the role of transcriptional kinetics and control in cell 
death or survival decisions after DNA damage 
 
The cell death/survival decision process after DNA damage is a complex one, involving many 
signaling proteins as well as drastic changes in the transcriptional state of the cell (37,57). Other 
complex biological processes, such as signaling cascades affecting cell death or growth in 
response to external stimuli, have previously been successfully studied using systems 
measurements and computational modeling techniques (75-77). Stimulated by these studies, we 
decided to apply a systems-level approach to better understand the temporal transcriptional co-
ordination of various DNA damage response pathways as well as the involvement of a wide 
range of cellular processes in cell death/survival decision processes. 
 
With the knowledge that significant genome-wide transcriptional changes occur after DNA 
damage, we decided to measure global transcriptional changes in human cells after DNA damage 
induced by a chemotherapeutic agent, 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU). Our 
decision to study transcription was motivated not only by the potential role of transcription in 
cell decision processes but also by the fact that, at the beginning of the project, whole genome 
microarray technology was the accepted and readily available method available for systems-wide 
transcription measurements. Computational methods could then be applied to the large data set 
generated in this manner, to extract pertinent information about the transcriptional signatures for 
cell death or survival after DNA damage. Additionally, the unbiased nature of genome-wide 
measurements would also facilitate the discovery of novel pathways and processes important in 
the decision between cell death and survival.  
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The approach we took to study the transcriptional control of cell death or survival after DNA 
damage was to compare transcriptional kinetics between DNA damage sensitive cells that are 
destined to die and resistant cells that are destined to survive in the presence of damage, 
anticipating that this might give us insight into temporal gene expression changes related to cell 
death or survival. This approach has been used successfully by us and others to identify genes 
that can accurately differentiate between distinct populations (78-81). The DNA damaging agent, 
cell lines and computational techniques we used to generate a genome-wide transcriptional data 
set and study transcriptional kinetics in damage sensitive or resistant cell lines are discussed 
below. 
 
1.3.1 BCNU as a DNA damaging agent and a chemotherapeutic agent 
 
1.3.1.1 Cellular reactions of BCNU 
 
BCNU is a member of the chloroethylnitrosoureas (CENUs), known to generate nucleophilic 
chloroethylenium ions in aqueous solutions that react with DNA to produce a wide range of 
DNA lesions (82). CENUs also react with and inhibit protein function by carbamylating them at 
cysteine residues. 
 
Although BCNU can react with both cellular proteins and DNA, the major biologically and 
clinically relevant reactions are thought to be the DNA interstrand crosslinks generated by 
BCNU (83). These crosslinks are generated in a multi-step process (Figure 1.2), the first of 
which is the formation of the O6-chloroethylguanine DNA lesion (84). This intermediate 
undergoes intramolecular rearrangement to form 1-O6-ethanoguanine which in turn reacts with 
cytosine in the complementary DNA strand to from a G-C interstrand crosslink (82,84). The final 
interstrand crosslinks are hard to repair and contribute to cellular cytotoxicity by BCNU. 
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The steps in the formation of interstrand cross-links by BCNU. The figure also shows the intermediate 
that can be successfully removed by MGMT (modified from 150). 
Figure 1.2 Mechanism of BCNU interstrand cross-link formation  
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1.3.1.2 DNA damage response mechanisms initiated by BCNU lesions 
 
Multiple studies have shown that the repair of O6-chloroethylguanine lesions by the O6-
methylguanine DNA methyltransferase protein (MGMT) prevents DNA interstrand crosslink 
formation. Cells expressing high levels of the MGMT protein are, in fact, resistant to BCNU 
treatment (85-87). In the absence of MGMT, the reaction proceeds to completion and interstrand 
crosslinks are formed. These ICLs are extremely toxic because they induce severe replication 
stress, inhibit transcription and are hard to repair and resolve. The repair mechanisms employed 
to remove these ICLs are not known yet but are thought to include nucleotide excision repair and 
ICL repair mediated by the Fanconi anemia proteins and homologous recombination (88-90). 
Base excision repair is also thought to play a role in protecting cells from BCNU cytotoxicity 
(91). 
 
1.3.1.3 Chemotherapeutic application of BCNU 
 
The DNA inter-strand cross-links are particularly cytotoxic for cells undergoing frequent 
replication due to stalled replication and the formation of double-strand breaks (92,93). Because 
of its preferential cytotoxicity for rapidly dividing cells, BCNU is commonly used to treat 
glioblastomas. BCNU is lipophilic and can therefore easily cross through the blood brain barrier, 
making it more suitable for treating glioblastomas (94,95). Currently, the treatment regimen 
includes combination therapy with another DNA alkylating agent, temozolomide, radiotherapy 
and surgical resection. Even with these combination therapies, the average survival time of the 
patients is about one year (96-98). 
 
One of the drawbacks of BCNU is that tumor cells with functional MGMT are resistant to low 
doses of the drug (99,100). These types of tumors have been targeted by administering the 
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MGMT inhibitor, O6-benzylguanine, along with BCNU (101). Besides MGMT-mediated 
resistance of BCNU, another undesired outcome of BCNU treatment is the drastic side effects it 
causes such as myelosuppression (98).  
 
Few studies have measured the effects of BCNU treatment in healthy human cell lines. The DNA 
response mechanisms initiated in healthy cells, the mechanisms of cell cycle arrest or cell death 
and the factors responsible for the difference in side effects observed between patients in the 
clinic are not known.  Further study could reveal other factors that may improve BCNU 
treatment strategies by identifying tumors that will respond to BCNU treatment and patients that 
will have less severe side effects. Moreover, knowledge of factors that render blood and 
epithelial cells sensitive to BCNU could potentially identify targets to be inhibited or 
manipulated to ameliorate the severe and adverse side effects that currently limit cancer therapy. 
 
With this in mind, in this study, we used a panel of 24 cell lines derived from healthy, ethnically 
diverse humans to study factors that affect the sensitivity of healthy cells to BCNU, and to better 
understand the difference between cells that are sensitive and resistant in terms of their 
transcriptional kinetics, cell death initiation mechanism and cell cycle arrest after BCNU 
treatment. 
 
1.3.2 The experimental system - a panel of genetically varied cell lines 
 
A panel of twenty-four genetically diverse cell lines was used for this study in the hope that they 
could be used to find novel genes responsible for the cell death/survival decision mechanism. 
The 24 cell lines are a subset of a larger set of 450 lymphoblastoid cell lines derived from the 
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blood of healthy humans with ancestry from around the globe, and that maintains the genetic 
diversity of the panel. These cell lines were developed from B lymphocytes by EBV 
transformation. It has been observed that EBV transformation maintains p53 function and does 
not induce p53 mutations (102). Therefore, we believe that these cells induce proper DNA 
damage response mechanisms. Additionally, these cell lines have varying basal expression levels 
of hundreds of genes that could provide new information on novel mechanisms for cell death or 
survival after DNA damage. 
 
1.3.2.1 Cell survival of the panel of cell lines to various DNA damaging agents 
 
Previous studies showed that the 24 cell lines showed a wide range of sensitivity spanning from 
~10% to ~90% control growth when exposed to the alkylating agent N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG), an alkylating agent (79). By studying the expression of the four most 
sensitive and four most resistant cell lines, we found that there was a strong basal gene 
expression signature of 48 genes that could accurately predict the sensitivity of the remaining 
cell lines to MNNG. The panel of cell lines also showed a broad range of sensitivity to methyl-
methanesulfonate (MMS), another alkylating agent (Figure 1.3). Interestingly, the cell lines do 
not maintain order of sensitivity so that cell lines that were considered resistant for MNNG are 
not necessarily resistant to MMS treatment and vice versa. These observations show that the 
genetic variation present in the panel of cell lines provides an interesting and informative 
experimental system in which to study resistance or sensitivity to DNA damage. 
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MNNG sensitivity (79) (top) and MMS sensitivity (Unpublished data, Samson Lab) of the panel of cell 
lines. Cell lines are colored according to MNNG sensitivity to show the different order of sensitivity for 
MMS.(figure from Leona Samson) 
Figure 1.3 : The panel of cell lines shows a wide range of sensitivities to DNA alkylating agents 
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1.3.2.2 Studying DNA damage recovery in the panel of cell lines 
 
Based on the wide range of sensitivity observed for MNNG and MMS, we hypothesized that the 
panel of cell lines would show a similarly broad range of sensitivity to other DNA damaging 
agents. In particular we were interested in studying the range of sensitivity of these cell lines to 
the clinically prescribed DNA damaging agent, BCNU, used in cancer therapy. If indeed this was 
the case, we would have a set of cell lines with extreme BCNU sensitivity or resistance. The 
extremely sensitive cell lines would provide a platform to study transcriptional kinetics in cells 
that decide to die. Similarly, transcriptional kinetics measured in extremely resistant cells would 
provide insight into the decision to survive. With this as our experimental goal, we decided to 
screen the panel of cell lines for sensitivity to BCNU, and measure BCNU induced 
transcriptional changes in the two most sensitive and two most resistant cell lines to gain insight 
into the transcriptional control of cell death or survival after DNA damage. 
 
1.3.3 Computational approaches to better understand cell death/survival 
decisions after DNA damage 
 
Our goal was to use computational techniques to mine a large transcriptional data set to better 
understand transcriptional kinetics in the presence of DNA damage. A major challenge in 
microarray data analysis is the identification of meaningful signals from the confounding noise. 
This problem of feature selection has been studied extensively and is an area of active research. 
Some proposed methods of feature selection from microarray data include the use of genetic 
algorithms (103,104), principle component analysis (105-109), Bayesian methods (110,111) and 
numerous other techniques (112-114). These techniques try to identify the minimal subset of 
genes that incorporate the maximum information content from the data set.  
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Although such minimal subsets have applicability as biomarkers, they are not often sufficient or 
necessary to understand all of the important aspects about the biological system. Instead, simpler 
techniques such as statistically significant fold-changes are commonly used to identify genes that 
are differentially expressed between two biologically distinct conditions. We, and others, have 
successfully used this method on data sets consisting of multiple comparable measurements for 
each of two conditions (78-81). Some studies have also used statistically significant fold-change 
on time-series data to identify genes that are induced or repressed at a particular time-point 
between treated and control samples (115,116). Another commonly used technique for gene 
selection from time-series data is analysis of variance (ANOVA) (117-120). With ANOVA, 
genes that vary across multiple dimensions can be identified and studied in detail.  
 
Once an interesting and meaningful set of genes have been identified, network and enrichment 
algorithms are commonly used to identify the underlying pathways and cellular process that are 
described by a selected set of genes. For example numerous algorithms have been described that 
build networks from gene expression data based on co-expression, mutual information or 
biological functions (121-126). Additionally, platforms like Ingenuity Pathway Analysis 
(Ingenuity® Systems, www.ingenuity.com) can be used to build networks from data bases 
containing curated gene and protein interaction or regulation information. These methods allow 
the analysis of selected genes in terms of their underlying biology, thus facilitating a better 
understanding of their involvement in the biological system being studied.  
 
Besides gene-set selection and network identification, time-series microarray data is amenable to 
analysis by various other computational techniques, the choice of which depends greatly on the 
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biological question of interest. For example differential equation models of transcript kinetics 
have been used to predict transcription factor activity from gene expression measurements 
(127,128). Hidden Markov Models have also been used to build time-series expression trees 
separating or clustering together genes with similar expression (129). This and other clustering 
techniques give us the power to identify transcripts that follow similar expression patterns across 
multiple conditions, thus revealing genes that are co-regulated or that form interconnected 
modules involved in DDR. In fact, previous studies have used clustering analyses with 
expression data in yeast to identify core stress-response pathways or proteins induced under 
various stresses (130-132).  
 
For our data set, we implemented many of the afore-mentioned computational techniques to 
understand transcriptional changes upon exposure to a DNA damaging agent. First, we used 
statistical techniques to extract meaningful signals from the confounding noise. The statistical 
analyses were complemented with network and enrichment techniques to better understand 
cellular modules involved in the transcriptional response to DNA damage. These analyses 
directed us towards specific pathways that are transcriptionally activated or repressed to a greater 
extent in the sensitive cell lines as compared to the resistant cell lines after BCNU treatment.  
 
The transcriptional signature identified from our data was further used to identify transcription 
factors that might control expression of genes in the signature set. Transcription factors act as 
integrators of signals and are key regulators that can change the state of the cell based on the 
signals.  Knowledge of possible transcriptional regulators of the transcription signature in our 
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data set would give us insight into mechanisms that activate the cell death signature in cells that 
decide to die after DNA damage.   
 
Computational techniques have previously been used to predict putative transcriptional 
regulation of co-expressed gene sets in yeast as well as human cells (129,133,134). These 
techniques have been successful in yeast studies because of simpler transcriptional control in 
these single-celled organisms. Transcriptional regulation is more complex in human cells 
because of the increased number of transcription factors and the presence of more complicated 
and dynamic combinatorial regulatory complexes (135). However, our knowledge about 
transcriptional regulation in humans is continuously being improved. Chromatin 
immunoprecipitation followed either by microarray hybridization (ChIP-chip) or sequencing 
(ChIP-seq) experiments have provided data-sets to identify high confidence transcription factor 
binding motifs for many transcription factors in various cell types. These data have been curated 
in databases like TRANSFAC (136-139)  and JASPAR (140-143), from which high confidence 
position weight matrices have been calculated for transcription factors with available data.  Many 
computational techniques take advantage of these experimentally determined position weight 
matrices to predict putative transcription factors that regulate a set of co-expressed genes 
(144,145). For our data set, we used one such algorithm, PRIMA, which is built into the 
EXPANDER (146-149) package, to identify transcription factors whose binding sites were 
enriched within the promoter regions of genes in our signature set.  
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These computational techniques allowed the identification and interpretation of a transcriptional 
signature for BCNU induced cell death, and also provided a putative model for the 
transcriptional control of a subset of the transcriptional signature. 
 
1.4 Goals of the thesis and project design  
 
Using the set of 24 cell lines, DNA damaging agent and computational techniques described, the 
goal of this thesis was to identify transcriptional signatures that are characteristic of cell death or 
cell survival after DNA damage. This was systematically pursued following the steps below: i) a 
high-throughput assay was developed to measure the sensitivity of lymphoblastoid cell lines to 
genotoxic and cytotoxic agents; ii) The panel of 24 genetically varied lymphoblastoid cell lines 
were screened for sensitivity to BCNU; iii) a multi-dimensional data set was generated by 
making temporal transcriptional profile measurements in the two most sensitive and the two 
most resistant cell lines after BCNU treatment; iv) computational techniques were used to 
identify a biologically meaningful transcriptional signature for cell death after BCNU induced 
DNA damage; v) various functions represented in the transcriptional signature were 
experimentally shown to explain the phenotypic cell behavior after DNA damage; vi) using 
computational and experimental techniques, Nuclear Factor Y was identified as a putative 
regulator of a subset of genes in the cell death signature, and a possible model for transcriptional 
regulation was proposed. 
 
These steps are described in detail in Chapter 2 (step (i)) and Chapter 3 (steps (ii) to (vi)). 
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Chapter 2:   A High-Throughput Survival 
Assay to Measure Drug-induced Cytotoxicity 
and Cell Cycle Effects 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contributions: Chandni R. Valiathan developed the flow cytometry protocol for suspension 
cells. Jose L. McFaline optimized parameters for adherent cell lines. 
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2.1 Abstract 
 
We describe a high-throughput method to accurately measure the cytotoxicity induced in 
mammalian cells upon exposure to various drugs. Using this assay, we obtain survival data in a 
fraction of the time required to perform the traditional clonogenic survival assay, long considered 
the gold standard. The dynamic range of the assay allows sensitivity measurements on a multi-
log scale allowing better resolution of comparative sensitivities. Moreover, the results obtained 
contain additional information on cell cycle effects of the drug treatment. Cell survival is 
obtained from a quantitative comparison of proliferation between drug-treated and untreated 
cells. During the assay, cells are treated with a drug and following a recovery period allowed to 
proliferate in the presence of bromodeoxyuridine (BrdU). Cells that synthesize DNA in the 
presence of BrdU exhibit quenched Hoechst fluorescence easily detected by flow cytometry; 
quenching is used to determine relative proliferation in treated versus untreated cells. Finally, 
this assay can be used in high-throughput format to simultaneously screen multiple cell lines and 
drugs for accurate measurements of cell survival and cell cycle effects after drug treatment. 
 
ABBREVIATIONS 
PI- propidium iodide; CEN - chicken erythrocyte nuclei; BCNU – 1,3-bis(2-chloroethyl)-1-
nitrosourea 
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2.2 Introduction 
 
Survival of cells upon exposure to toxic agents is an important phenotypic measure used to 
understand the biological importance of certain proteins and pathways in either preventing or 
enabling cell survival after toxic stress. For example, key proteins involved in DNA repair or the 
DNA damage response have been identified by measuring the effect of silencing or over-
expressing these proteins on cell survival after DNA damage. The gold standard for assessing the 
survival of cells after drug treatment in continues to be the clonogenic survival assay that is 
extremely sensitive and has a dynamic range of several orders of magnitude. Unfortunately, it 
suffers from being very low throughput as well as time and labor intensive. Typically, the 
clonogenic survival assay takes 10-14 days and requires a large number of cell culture plates, 
thus limiting its practical application to a few cell lines and to a limited number of doses or 
agents.  Moreover, for cells grown in suspension or, those that fail to form colonies, the 
clonogenic survival assay is done by either monitoring growth from single cells or by following 
their ability to form colonies in soft agar. These approaches are even more time intensive taking 
up to 3-4 weeks to complete a single experiment (1). Currently, the only available high-
throughput techniques for measuring sensitivity involve the correlation of viability to membrane 
permeability (trypan blue or propidium iodide exclusion) or measurement of metabolic activity 
(MTT assay). Unfortunately, membrane permeability only takes into account cells that undergo 
cell death after treatment and fails to identify sensitivity due to activation of a static program 
such as arrest or senescence, and metabolic activity primarily reflects mitochondrial function. 
Furthermore, changes in metabolic activity do not always correlate well with cell viability after 
treatment and also does not differentiate between cytotoxic and static effects after treatment (2). 
Moreover, these methods have an inherently limited dynamic range for detection of sensitivity, 
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generally less than a single order of magnitude versus three or four orders of magnitude for the 
clonogenic survival assay.  
 
In this paper, we describe a high-throughput method for measuring the sensitivity of cells to a 
wide variety of agents with a dynamic range comparable to that of the clonogenic survival assay. 
In addition to obtaining survival information, it can also be used to deduce cell cycle effects of 
drug treatment. This method is based on the fact that the fluorescence of Hoechst, a dye that 
preferentially binds AT-rich regions in the DNA, is quenched when bromodeoxyuridine (BrdU), 
a thymine analog, is incorporated into AT-rich regions (3,4). Cells that have divided zero, one or 
two times in the presence of BrdU can be differentiated based on the level of quenched Hoechst 
fluorescence, thus giving a measure of cell proliferation (5). In a previous report, Poot et al. (6) 
took advantage of the Hoechst quenching property of BrdU to measure survival of cells after 
exposure to a DNA damaging agent. We have extensively modified the technique to be 
performed in a multi-well format (96-well plate for suspension cells and 24-well plate for 
adherent cells), drastically decreasing the setup time and reducing the number of cells required 
for a survival curve to as little 106-3x106 cells. Furthermore, we have broadened the scope of the 
assay to simultaneously be used with different cell types and different cytotoxic agents. The 
assay can be completed within half the time taken to perform a clonogenic survival assay while 
maintaining high sensitivity and a dynamic range of three to four orders of magnitude.  
 
Figure 2.1 shows a concise representation of the steps involved in the assay. After cells are 
treated they are allowed to recover for the duration of two doubling times and subsequently 
allowed to proliferate (if they can) for the duration of another two doubling times in the presence 
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of BrdU. To make our approach amenable to screening multiple agents with diverse mechanisms 
of actions we allow cells two doubling times after treatment for drug toxicity to present itself. 
This allows for simultaneous detection of the toxicity of agents that act immediately versus those 
that require formation of intermediates to slowly build up in cells. As an example, various DNA 
damaging agents are dependent on replication for toxicity to occur, and more than one round of 
replication may be needed to generate an observable phenotypic response. The duration of time 
prior to BrdU addition can be optimized depending on the agents to be tested. Cells are then 
gently lysed to obtain nuclei which are stained with propidium iodide (PI) and Hoechst dye.  
Nuclei fluorescence is measured by flow cytometry to quantify the percentage of cells that have 
proliferated in the presence of BrdU. The relative proliferation rate of treated samples compared 
to untreated controls gives a measure of the sensitivity of cells to treatment. The ease, economy 
and efficiency of this assay will enable rapid progress in systematic approaches to understanding 
the biological importance of many proteins and pathways whose modulation leads to an observed 
phenotype after exposure to cytotoxic agents. 
 
2.3 Materials and methods 
 
2.3.1 Cell culture 
 
The lymphoblastoid cell lines TK6 and two TK6 derivatives (MT1 and TK6+MGMT) were 
grown in suspension in RPMI medium supplemented with 10% equine serum, 1% l-glutamine 
and 1% penicillin-streptomycin. The adherent U87MG glioblastoma cell line was grown in 
DMEM medium supplemented with 15% fetal bovine serum, 1% l-glutamine and 1% penicillin-
streptomycin.  
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Time line showing key steps in the experimental procedure 
Figure 2.1: Experimental set up with anticipated timing 
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2.3.2 Determining the optimal BrdU concentration 
 
Cells were grown in the presence of different concentrations of BrdU (0-100µM) for a little 
longer than one doubling time, then lysed and stained as described below with Hoechst and 
propidium iodide for flow cytometry analysis. The optimal BrdU dose was determined as that 
which quenched Hoechst fluorescence of G1 cells by half after one doubling time; this dose 
allows the effective resolution of cells that have undergone one division after BrdU addition 
from those that have undergone none or two divisions after addition. The optimal dose was 
determined as 45µM for TK6 and the TK6 derivatives, and 20µM for the U87MG cell lines.  
 
2.3.3 Cell cycle profile analysis by flow cytometry 
 
BrdU is sometimes known to cause a G2/M arrest in cultured human cells. TK6, TK6 derivatives 
and U87MG cell lines were grown in the presence of the optimal BrdU concentration for at least 
two doubling times, during which samples were collected at multiple time points, washed with 
cold PBS and fixed overnight in cold 100% ethanol. Fixed cells were washed with PBS+1% 
BSA, resuspended in PBS+1%BSA containing propidium iodide (50 µg/ml) and immediately 
analyzed by flow cytometry to obtain cell cycle profiles. None of the cell lines showed a G2/M 
arrest when grown in the presence of BrdU. If however such an arrest is observed, the effect can 
be overcome by adding deoxycytidine at an equal concentration as the added BrdU. 
 
2.3.4 Drug treatment 
 
Cell lines were treated in duplicate at multiple doses of BCNU (100mM in 100% ethanol). A 
maximum of six doses were assayed and therefore 12 wells were used for each survival curve. 
Treatment was performed in serum free media for one hour after which the drug was washed 
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away and the cells were grown in fresh serum-containing media. This treatment scheme can be 
accommodated for cytotoxic agents that require longer exposure times as well as short-lived 
agents that do not require to be washed away after treatment. The drug treatment procedure is 
described below for suspension or adherent cell lines.  
Suspension cells: Before drug treatment, cells were grown to mid-log phase (6x105cells/ml for 
TK6 and its derivatives). 270 µl of cells at a density of 4.5x105cells/ml were plated in each well 
of one row of a round-bottom 96-well plate. If multiple cell lines were assayed, each cell line 
was plated in one row of a 96-well plate in serum-free media. The drug was diluted to 10X of the 
final dose concentrations in serum-free media in another 96-well plate. 30µl of the 10X drug was 
transferred to each well in the 96-well plate containing cells, after which the cells were incubated 
at 37oC for 1h. After 1h, cells were spun down at 1200rpm for 5min, drug-containing media was 
removed using a multi-channel pipette and the cells were washed with 200µl warm 1XPBS per 
well. The cells were then resuspended in 300ul of warm fresh media containing serum, 
transferred to a flat-bottom 96-well plate and incubated at 37oC for the duration of two normal 
doubling times. If the drug is not to be washed away, the experiment is set up in a flat-bottom 
96-well plate at a density of 1.7x105cells/ml in serum containing media, and the washing step is 
omitted.  
Adherent cells: Before drug treatment, U87MG cells were grown to 80% confluence, washed 
with warm 1XPBS, trypsinized and diluted to 4x104cells/ml. 1ml of the diluted cells were plated 
in each well of a 24-well plate and cells were allowed to attach overnight at 370C, 5% CO2. One 
such 24-well plate can be set up for each cell line being assayed. At the time of treatment, the 
cells were removed from the incubator and the media replaced with 900µl of warm, fresh serum-
free media. The drug was diluted to 10X the final dose concentrations and 100µl of the 10X drug 
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was added per well such that there were duplicate wells per dose and six doses, including the 
untreated control. The cells were returned to the incubator for the duration of 1h after which the 
drug-containing media was replaced with warm serum-containing media. The cells were returned 
to the incubator for a period of time equivalent to two doubling times for normally growing cells.  
 
2.3.5 Bromodeoxyuridine Addition 
 
After allowing cells to respond for two doubling times after drug treatment, the cells are 
incubated in the presence of BrdU for another two doubling times. The optimal BrdU 
concentration was determined to be 45µM for TK6 and its derivatives, and 20µM for U87MG 
cells. If the optimal BrdU concentration is greater than 20µM, then BrdU must be replenished 
every 12 hours. Therefore, after the first two doubling times, BrdU was added to TK6 and TK6 
derivatives at a concentration of 45µM(from a 10mM stock) and replenished by simply adding 
BrdU to each well every 12 hours for the duration of two normal doubling times. Similarly BrdU 
was added to U87MG cells at a concentration of 20µM. Since cells become photosensitive upon 
BrdU addition, care must be taken to keep cells in the dark at all times post BrdU addition. 
 
2.3.6 Nuclei isolation and staining for flow cytometry 
 
At the end of four doubling times after drug treatment, cells were transferred to a v-bottom 96-
well plate. For suspension cells, the cells were transferred directly to a v-bottom 96-well plate 
using a multi-channel pipette. For adherent cells, the cell plate was spun down at 1500rpm for 
5min to pull down any unattached cells. The media was removed and replaced with 100ul of 
trypsin EDTA. Trypsin was quenched with 200µl of serum-containing media and the cells from 
one well in the 24-well plate were transferred to one well in the v-bottom 96-well plate. Once 
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transferred, both cell types were spun down at 1500rpm for 5min, media was removed with a 
multi-channel pipette and cells were washed with cold 1XPBS. The cells were then resuspended 
in 300µl of 1X lysis/staining buffer (0.1M Tris HCl pH 7.5, 0.1% Igepal CA-60, 1mM CaCl2, 
5mM MgCl2, 0.2%BSA (w/v), 1.2ug/ml Hoechst 33258 and 1x104 chicken erythrocyte nuclei 
(CEN)/ml) and incubated on ice for 15 minutes after which 6ul of 200µg/ml propidium iodide 
was added to each well using a multi-channel pipette. Two wells containing only the 
lysis/staining buffer and propidium iodide are also prepared as blanks. Samples were mixed well 
using a multi-channel pipette and analyzed on a BD LSR II flow cytometer equipped with a 96-
well plate robot arm.  
  
2.3.7 Data collection 
 
Events were visualized on the side scatter vs. forward scatter plot to gate out debris (Figure 
2.2a), and on the PI-height vs. PI-area plot to exclude doublets that fall below the diagonal 
(Figure 2.2b). 30,000 events that passed these two criteria were collected and viewed on a PI-
Area vs. Hoechst-Area plot (Figure 2.2c). During data collection, the voltages for PI and Hoechst 
were adjusted to position CEN at the (30K, 30K) point to facilitate subsequent data analysis. 
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a) Side scatter vs. forward scatter plot shows the position of nuclei, CEN and debris. All events in gate R1 
are to be included in the data collection and analysis steps.b) PI-Height vs. PI-Area plot shows the doublet 
events below the diagonal that must be excluded. Events in gate R2 are included in the data collection and 
analysis steps. c) PI-Area vs. Hoechst-Area plot of events included in gates R1 and R2. PI and Hoechst 
channel voltages must be adjusted to position CEN at (30K, 30K) or any other practical coordinates for all 
samples. 
Figure 2.2: Data filtering and collection plots 
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2.4 Results 
 
2.4.1 Detecting cells that have undergone zero, one or two cell divisions 
after drug treatment 
 
BCNU is a DNA damaging agent commonly used in the clinic to treat glioblastoma despite the 
fact that it can have severe side effects on hematopoietic cells (7,8). We used the multi-well 
assay to test the BCNU sensitivity of the human lymphoblastoid cell lines TK6 and TK6 
derivatives (MT1 and TK6+MGMT) that grow in suspension and the human U87MG 
glioblastoma cell lines that grow attached. All data were analyzed using FlowJo (TreeStar Inc). 
For each cell line and drug dose, the debris and doublets were gated out as described in Figure 
2.2. The remaining events were observed on a PI-Area vs. Hoechst-Area plot. Figure 2.3 
delineates the regions corresponding to cells that are in the first, second or third cell cycle after 
treatment, recovery and incubation with BrdU. As seen in Figure 2.3A, Hoechst fluorescence of 
cells decreases as they replicate their DNA in the presence of BrdU. Therefore, as the cells 
replicate and divide, they move from the region labeled 1st cell cycle leftwards to the region 
labeled 2nd cell cycle, and so on.  For each sample, gates were drawn as in Figure 2.3C and the 
number of events in each gate was determined. 
 
2.4.2 Calculating the fraction of proliferated cells after drug treatment 
 
For each cell type and dose assayed, the number of events in each of the regions corresponding 
to the 1st, 2nd or 3rd cell cycle was used to calculate the number of proliferating cells in the 
sample as shown in formula 1.  
Formula 1 
½*(#events in cell cycle 2/#CEN)+ ¼*(#events in cell cycle 3/#CEN) 
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A) PI-Area vs. Hoechst-Area plot showing the regions that would contain nuclei in the first cell cycle 
(CC1)- light grey, second cell cycle (CC2)- dark grey, third cell cycle (CC3) black. B) This plot shows 
the G1, S and G2 populations for each cell cycle. G11, S1, G21 are G1, S and G2 in cell cycle 1 and so on. 
C) Example of a sample for which the CEN and cell cycle gates have been drawn. 
 
Figure 2.3: Gates delineating cell cycle regions for the data analysis 
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The formula calculates the total number of cells that have divided after drug treatment by halving 
the number of cells in the 2nd cell cycle (these cells have undergone one cell division) and 
dividing the number of cells in the 3rd cell cycle by four (these cells have divided twice). Since 
all samples of equal volume were spiked with the same number of CEN, the number of CEN 
counted per sample is proportional to the volume of sample used for flow cytometry data 
collection. Therefore the density of proliferating cells is calculated by dividing the total number 
of proliferating cells per sample by the number of CEN counted in that sample. Comparing the 
density of proliferated cells in a treated sample with that in an untreated sample gives the % 
control growth value that is used to plot a survival curve.  Example calculations for the survival 
curves are shown in Table 2.1. 
 
2.4.3 The multi-well assay has a large dynamic range, yielding log scale 
killing for suspension and adherent cell lines treated with a cytotoxic 
agent 
 
BCNU’s efficacy as a chemotherapeutic agent arises from its ability to generate extremely 
cytotoxic DNA inter-strand crosslinks (9). DNA crosslinks are formed in a multistep process, the 
first of which is the formation of O6-chloroethylguanine lesions (10). The O6-methylguanine 
methyl transferase (MGMT) protein is known to remove chloroethyl adducts from the O6 
position of guanine (11,12). Thus, MGMT provides protection against BCNU-induced 
cytotoxicity, and cells lacking MGMT are particularly sensitive to BCNU (13-15). With this in 
mind, we used our multi-well assay to measured BCNU sensitivity of cell lines either lacking or 
expressing MGMT to determine the range of sensitivity accurately measured by the assay. 
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Table 2.1 Example showing the process of calculating % control growth of treated samples. 
 
Sample-
dose(µM) CEN CC2 CC3 A=CC2/CEN B=CC3/CEN Nd=A/2+B/4 P=100*(Nd/Nd=0) 
MT1-0 2852 3461 19049 1.21353436 6.67917251 2.27656031 100 
MT1-25 11075 602 74 0.05435666 0.00668172 0.02884876 1.26720818 
MT1-50 8543 24 0 0.00280932 0 0.00140466 0.06170093 
TK6+MGMT-0 2128 10463 8881 4.91682331 4.17340226 3.50176222 100 
TK6+MGMT-25 2106 8950 8183 4.24976258 3.88556505 3.09627255 88.4204113 
TK6+MGMT-50 2631 12822 8030 4.87343216 3.05207146 3.19973394 91.3749633 
 
Data for survival curves shown in Figure 2.4. CEN: Chicken Erythrocyte Nuclei; CC2: number of events in cell 
cycle 2; CC3: number of events in cell cycle 3; Nd: number of cells that divided; P: percentage of proliferating 
cells in a treated versus untreated sample. 
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BCNU sensitivity of suspension (TK6 and MT1) and adherent (U87MG) cell lines that lack 
MGMT was measured using our multi-well assay. The TK6 and MT1 cell lines have previously 
been shown to be extremely sensitive to BCNU in the clonogenic survival assay as shown in 
Figure 2.4A (16). Results from our multi-well assay, shown in Figure 2.4B, are remarkably 
similar to those from the colony-forming assay. Additionally, we measured BCNU sensitivity of 
the TK6+MGMT cell line (TK6 cell line reconstituted with MGMT) using our multi-well assay 
and found that TK6+MGMT cells show extreme resistance to BCNU, as expected (Figure 2.4B). 
We also tested the assay on adherent cells by measuring BCNU sensitivity of the adherent 
U87MG glioblastoma cell line that lacks MGMT (17). Again, as expected the U87MG cells 
showed extreme BCNU sensitivity (Figure 2.4), also with multi-log-scale killing.  
 
2.4.4 The multi-well assay detects cell-cycle effects of drug treatment  
 
Flow cytometry plots obtained using our assay for U87MG cells treated with BCNU show that 
with increasing doses of BCNU, there is not only a decrease in the total number of cells but that 
this decrease is also accompanied by a steady increase in the fraction of cells in late S and G2/M 
phase of the first cell cycle (Figure 2.5). From these observations we can conclude that at higher 
BCNU doses, surviving cells are unable to divide during the BrdU pulse and remain in the region 
corresponding to the first cell cycle. Moreover, surviving cells are arrested at late S or G2/M for 
the entire duration after BrdU addition. 
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(A) Killing curves for BCNU treatment of TK6 and MT1 cell lines using the traditional clonogenic 
survival assay (reproduced from (13)); (B) Killing curves for BCNU treatment of the TK6, MT1 and 
TK6+MGMT cell lines using the multi-well assay; (C) Killing curves for BCNU treatment of the U87MG 
glioblastoma cell line using the multi-well assay. 
Figure 2.4: Example of data obtained using the assay 
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U87MG cells show accumulation in late S or G2/M with increasing doses of BCNU. This information is 
obtained from the survival data with no additional experiments. 
Figure 2.5: Cell cycle effects of BCNU on U87MG cells 
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2.5 Discussion 
 
The use of survival measurements is a key method implemented to determine the effect that a 
gene product has on the phenotypic outcome of cell death. The bottleneck in these studies is 
usually the method used to measure cell survival. The clonogenic survival assay, long considered 
the gold standard in the field, takes 10-14 days and can only be performed for a few cell lines 
and few doses at any one time due to the long and laborious setup procedure. Moreover, the 
assay becomes troublesome for cells that do not form colonies or that grow in suspension, where 
cells must be plated at single cell densities or in soft agar to count colonies (1). To get around 
this time-consuming assay, people have resorted to other higher-throughput techniques such as 
measuring membrane permeability or metabolic (mitochondrial) activity; while these assays are 
quicker, they have limited dynamic range such that cells that with drastically different 
sensitivities on a log scale may be considered as only moderately different on the linear scale. 
 
The multi-well assay we describe here produces survival measurements on a multi-log scale 
comparable to the clonogenic survival assay. As described in the results section, BCNU 
sensitivities of the suspension cell lines TK6 and MT1 are remarkably similar to that measured 
by the clonogenic survival assay. Moreover, the TK6+MGMT cell line is identified as being 
resistant to BCNU treatment as expected (13,15). These results highlight three important aspects 
of our assay: i) The assay can measure sensitivity and resistance equally well, thus yielding 
accurate results that reflect those obtained from the clonogenic survival assay; ii) the multi-well 
assay is capable of measuring cell sensitivity on a multi-log scale, thus showing the large 
dynamic range the assay has in contrast to other available quick assays; iii) the assay can be used 
to measure cell survival of both suspension and adherent cell lines to cytotoxic agents, thus 
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increasing its applicability. The assay has a reduced setup time and requires fewer cells allowing 
one to simultaneously assay a large number of cell lines, doses and agents. This greatly improves 
cell survival measurement efficiency to yield results in a fraction of the time and in a less labor-
intensive manner as compared to the clonogenic survival assay. 
 
In addition to inducing cell death, many cytotoxic agents affect regular cell cycle progression, 
with cells undergoing arrest either in the G1, S or G2/M phases of the cell cycle. The nature of 
the arrest changes with the drug or cell line used, and provides insight into mechanisms of drug 
action and possible ways to modify cell sensitivity to a particular drug. Traditional colony-
forming survival assays as well as more recent high-throughput survival assays yield no 
information on possible cell cycle arrest from the drug treatment. Any such cell cycle effects 
have been determined by separate and additional experiments such as cell cycle profile 
measurements. In comparison, results from our multi-well assay are extremely rich in cell-cycle 
information, and therefore provide added insight into the long-term cell cycle effects of the drug 
treatment.  
 
The data obtained using our assay showed, as seen in Figure 2.5, that the U87MG glioblastoma 
cell lines show a decrease in total number of cells, accompanied by a concomitant arrest in late 
S/G2 phase of the cell cycle. Previous studies have shown that U87MG cells show an 
accumulation of cells in late S or G2/M after BCNU treatment (18) (assayed by PI staining and 
cell cycle profile analysis by flow-cytometry). However, it is important to note that after 
determining cell sensitivity to BCNU using the colony forming assay, additional experiments 
were needed to determine the cell cycle effect of BCNU in U87MG cells.  In contrast, our assay 
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yields the same observations in addition to the survival measurements with no additional time 
and effort.   
 
In conclusion, we have presented a high throughput method that takes advantage of current flow 
cytometry technology and properties of proliferating cells to measure the sensitivity of both 
suspension and adherent cells to different cytotoxic agents. The flexibility of the method, its 
large dynamic range and its broad applicability makes it a powerful tool with great potential in 
many different applications including both small and large scale screening of sensitivity of 
numerous cell lines to numerous toxic agents. 
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3.1 Abstract  
 
In the presence of DNA lesions generated by exogenous and endogenous agents, transcriptional 
changes are extremely important for the proper control of cell cycle progression and cell 
death/survival decisions. To better understand temporal kinetics and control of transcription after 
exposure to a chemotherapeutic agent BCNU, differences in expression kinetics between BCNU 
sensitive and BCNU resistant cell lines were studied. This led to the identification of a 
transcriptional signature that correlated with the observed cellular phenotype in BCNU sensitive 
and resistant cell lines. Furthermore, NF-Y was identified as a putative regulator of mitotic genes 
that were down-regulated in BCNU sensitive but not resistant cell lines, and thus implicated in 
the observed stalling of entry into mitosis. 
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3.2 Introduction 
 
Constant damage to the DNA in our cells from exogenous and endogenous agents elicits DNA 
damage response (DDR) mechanisms that include the induction of DNA repair, initiation of cell 
cycle checkpoints, chromatin remodeling and activation of transcription. The prominent role of 
the transcriptional response to DNA damage is seen by the significant genome-wide 
transcriptional changes induced upon exposure to DNA damaging agents in yeast and 
mammalian cells, not only for genes involved in DNA damage related functions like DNA 
repair, cell cycle arrest and apoptosis, but also in other cellular processes such as protein 
degradation and metabolism (1-4). In addition to the increased incidence of mutated transcription 
factors in cancer (5), the increased sensitivity to DNA damaging agents of yeast strains that were 
silenced in genes involved in transcription regulation (6,7) shows the importance of 
transcriptional control in rescuing a cell from DNA damage.  
 
Although cell-wide responses have been observed transcriptionally and are known to be 
important for cell decision processes after DNA damage, the mechanisms by which these 
decisions are made is not understood well. Moreover, the transcriptional control of these wide 
spread gene expression changes is still an area of active research. 
 
In this study, we set out to identify a transcriptional signature that was differentially induced or 
repressed over time in cells with extreme sensitivity or resistance to the chemotherapeutic agent 
BCNU. We went a step further to confirm that the signature gene set we identified indeed 
correlated with the cellular phenotype. We also attempted to identify a mechanism for the 
transcriptional regulation of the signature set in the presence of DNA damage. 
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3.3 Materials and Methods 
 
3.3.1 Cell culture 
 
Lymphoblastoid suspension cell lines were grown in RPMI medium (Invitrogen) supplemented 
with 15% FBS, supplemented with penicillin-streptomycin and L-glutamine. All cell lines were 
in the mid-log phase of growth prior to treatment. 
 
3.3.2 Proliferation assay 
 
Survival curves for the panel of 24 cell lines were obtained using the proliferation assay 
described in Chapter 2. Briefly, cells were plated in a 96-well plate and treated with 0, 10, 20, 40, 
60 and 80µM BCNU for one hour in serum-free media. After this, the drug was washed away 
and the cells were resuspended in warm serum-containing media. The cells were allowed to 
recover for two normal doubling times and then grown in the presence of BrdU (Sigma-Aldrich 
B5002) for another two doubling times. At the end of this, the cells were lysed in lysis buffer 
(0.1M Tris HCl pH 7.5, 0.1% Igepal CA-60, 1mM CaCl2, 5mM MgCl2, 0.2%BSA (w/v), 
1.2µg/ml Hoechst 33258, 1x104 chicken erythrocyte nuclei/ml), nuclei were stained with 
100µg/ml propodium iodide (Sigma-Aldrich P4170) and data was collected by flow cytometry. 
 
3.3.3 Cell cycle profile analysis 
 
Cells were spun down at 1500 rpm for 5min, washed with cold 1XPBS and fixed in 100% cold 
ethanol while vortexing. Cells were fixed overnight at 40C, after which they were washed twice 
with 1XPBS+1%BSA and stained in 1XPBS containing 50µg/ml propidium iodide and 1mg/ml 
RNAseA (Invitrogen). Samples were protected from light and analyzed by flow cytometry. 
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3.3.4 Drug treatment 
 
Cells were grown to mid log-phase prior to drug treatment. On the day of treatment, cells were 
spun down at 1500rpm for 5min and diluted to 4.5x105cells/ml in warm serum free RPMI 
medium. BCNU (100mM stock in 100% ethanol; Sigma-Aldrich C0400) was added directly to 
cells at a concentration of 40µM. Mock-treated samples were set up in the same manner as 
treated samples, except that 100% ethanol was added to cells instead of BCNU. After an hour-
long BCNU exposure, the drug was washed away and cells were re-suspended in fresh RPMI 
medium supplemented with 15% FBS. Cells were collected at the each time-point following the 
appropriate protocol for each assay. 
 
3.3.5 RNA isolation and hybridization  
 
Cell lines 4, 5, 13 and 16 were treated with 40µM BCNU as described. At each time point, two 
million cells were collected on ice and lysed in TRIzol® Reagent (Invitrogen). Samples were 
stored at -800C until all samples for the time-course were collected. RNA was isolated using the 
Qiagen RNeasy Mini kit and checked for integrity on the Agilent BioAnalyzer 2100. All samples 
that passed quality control were prepared using the NuGEN sample preparation procedure, and 
hybridized on Affymetrix HG-U133 plus 2.0 arrays. RNA quality control, sample preparation 
and array hybridization were performed at the BiomicroCenter, MIT. 
 
3.3.6 Microarray data analysis  
 
Normalization: Affymetrix .CEL files were uploaded to the GenePattern suite (8) and standard 
RMA normalization was used to normalize and extract expression values from the data set. Only 
probe-sets that were present in at least one sample were included in the analysis. The array data 
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was formatted into a three dimensional matrix in MATLAB (Mathworks). Similarly three 
dimensional matrices were used to store relevant gene information such as the time-point, drug 
dose and whether the expression value was measured in a sensitive or resistant cell line.  
Gene-set selection: ANOVA analysis was performed using the anovan function in MATLAB 
using the three dimensional matrices for gene expression values, BCNU dose, time-point and 
sensitivity. P-values for each of the variables (treatment, time and sensitivity) and for the 
different combinations of the variables (e.g treatment X time) were obtained. Probe-sets that 
passed a p-value cutoff of p < 0.01 for the treatment X sensitivity or treatment X sensitivity X 
time variables were selected for further analysis. 
Clustering: The hierarchical clustering module from the GenePattern suite was used to cluster 
along the rows of log-normalized data (log2 (gene value at time t/gene value at time 0)). 
Clustered data were exported and visualized using MATLAB. Similarly, the transcriptional 
signature was clustered using CLICK within the EXPANDER platform (9-12) to identify clusters 
of up-regulated and down-regulated genes. These clusters were used for the Ingenuity Pathway 
Analyses, Gene Ontology Enrichment and transcription factor binding site enrichment. 
Ingenuity Pathway Analysis: The set of 984 probe-sets as well as the up-regulated and down-
regulated clusters were analyzed using Ingenuity Pathways Analysis (Ingenuity® Systems, 
www.ingenuity.com) for network connectivity and canonical pathway enrichment analysis. 
Eligibility settings were chosen to be stringent, only allowing interactions and findings seen in 
human cell lines. 
Gene Ontology Enrichment: Gene ontology enrichment for biological processes was performed 
using the Database for Annotation, Visualization and Integrated Discovery (DAVID v6.7; (13)). 
The standard GO-FAT enrichment within DAVID was used, which focuses on enrichment of 
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more specific GO terms within the provided gene set by filtering out broader terms that might 
over-shadow the lower-level terms. 
Gene Set Enrichment Analysis (GSEA): The GSEA algorithm (14) available from the 
GenePattern Suite (Broad Institute) was used to check enrichment of genes that are repressed by 
p53 acetylation within the set of 984 differentially expressed probe-sets. Gene expression values 
at 48hours were used as the input and gene-wise permutations were performed for the 
enrichment analysis.  
 
3.3.7 Annexin/7AAD assay for measuring cell death 
 
At each time point,  cells were collected (1500rpm, 5min) and washed once in cold Annexin 
buffer (10mM HEPES, 140mM NaCl, 2.5mM CaCl2). Cell pellets were then incubated with 
7AAD (50µg/ml; Sigma A9400) and PE-AnnexinV (1:20 dilution; Invitrogen A35111) for 15 
minutes at room temperature, protected from light. Cells were immediately analyzed by flow-
cytometry. 
 
3.3.8 Phospho-histone H3 for measuring the mitotic fraction 
 
At each time point, cells from mock-treated and treated samples were collected (1500rpm, 
5minutes) and washed once with cold 1xPBS. Cells were then fixed in 4% formaldehyde 
(prepared in 1XPBS), at room temperature for 15 minutes. Cells were spun down and washed 
once with 1XPBS, after which cell pellets were resuspended in 100% methanol and stored at -
200C until analysis by flow cytometry. To prepare cells for flow cytometry, samples were spun 
down to remove methanol, and washed once in 1XPBS + 1% BSA. Cells were permeabilized by 
incubation in 1XPBS + 0.25% Triton for 15 minutes at room temperature. Cells were washed 
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once with 1XPBS + 1%BSA, and incubated with 0.75µg of anti-phospho-Histone H3 antibody 
(Upstate #06-570) for three hours at room temperature. After this incubation, cells were washed 
twice with 1XPBS + 1%BSA, and incubated with goat anti-rabbit IgG Alexa Fluor 647 (1:30 
dilution in 1xPBS + 1%BSA; Molecular Probes A21244) for 30 minutes at room temperature 
and protected from light. Samples were washed twice with 1XPBS and resuspended in 1XPBS 
containing 50µg/ml propidium iodide and 1mg/ml RNAseA. Cells were analyzed by flow 
cytometry. 
 
3.3.9 Immunoblot analysis 
 
At each time point, mock-treated and treated samples were collected (1500rpm, 5minutes), 
washed with 1XPBS and frozen in liquid nitrogen. Cell pellets were stored at -800C until lysis. 
Cells were lysed for 30 minutes on ice in lysis buffer (10mM Tris-HCl, pH8.0; 137mM NaCl; 
10% glycerol; 1% NP-40; 10mM EDTA; protease inhibitor cocktail; 10mM NaF; 1mM DTT; 
1mM sodium orthovanadate). The lysate was sonicated (3 times, 2 seconds each at 20% 
amplitude) to dissociate chromatin-bound proteins. Debris was pelleted by centrifuging samples 
for 10 minutes at maximum speed at 40C. Whole cell lysates were size-separated on 4-12% Bis-
Tris polyacrylamide gels (Invitrogen) and transferred onto nitrocellulose membrane (BioRad) for 
immunoblot analysis. The membrane was probed with the following primary antibodies: total 
p53 (Santa Cruz, sc-263), p-p53ser20 (R&D systems, AF2286), p-p53ser15 (R&D systems, 
AF1043), acetyl-p53lys373 (Millipore 06-916), beta-actin (Sigma A5441), and vinculin (Sigma 
V9131). Appropriate IRDye-conjugated secondary antibodies (Rockland) were used and the 
immunoblots were scanned and quantified using the Odyssey system (Licor Biosciences). 
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Positive controls were prepared from irradiated cells (10Gy) and cells treated with 50 μM 
etoposide (Sigma E1383) and 16.5nM TSA (Sigma T1953) for 12 hours. 
 
3.3.10 Chromatin immunoprecipitation followed by sequencing and peak 
calling 
 
Chromatin immunoprecipitation was performed using the Agilent mammalian protocol. Briefly, 
cells were cross-linked in 10% formaldehyde for 10 minutes at room temperature after which 
Glycine was added to quench cross-linking activity. Cells were washed with 1XPBS, aliquoted 
into tubes (108 cells per aliquote) and stored at -800C. Prior to immunoprecipitation, cells were 
permeabilized in lysis buffer (50mM Hepes-KOH, pH7.5, 140mM NaCl, 1mM EDTA, 10% 
glycerol, 0.5% NP-40, 0.25% Triton X and protease inhibitors) for 10 minutes at 40C, nuclei 
were washed and resuspended in sonication buffer (50mM Tris-HCl pH 8, 140mM NaCl, 1mM 
EDTA, 1% Triton X-100, 0.1% SDS, 0.1% Na-deoxycholate). Nuclei were sonicated to obtain 
chromatin fragments <500bp (36 cycles of 20 seconds on and 1 minute off at 45% amplitude). 50 
µl of the sonicated chromatin was saved as input control and the rest was incubated overnight 
with IgG (Sigma) or anti-NF-YA antibody (Rockland, 200-401-100) bound ProteinA-DynaI 
beads (Invitrogen). Beads were washed thrice with sonication buffer and one last time with a 
LiCl wash (20mM Tris pH 8, 1mM EDTA, 250mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate) 
and eluted in elution buffer(50mM Tris-HCl, pH 8, 10mM EDTA, 1% SDS) at 650C with 
vortexing. Crosslinks were reversed at 650C for 6 hours, and samples were treated with RNAse 
and proteinase K. Following this, DNA was isolated by phenol-chloroform extraction.  
 
Sample preparation, sequencing and preliminary data extraction was performed at the Biomicro 
Center, MIT on the Illumina sequencing platform. Aligned sequences from two NF-Y IPs and 
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two IgG control IPs were combined for Model-based Analysis of ChIP-Seq (MACS) (15) using a 
p-value cut-off of 10-10. The 200 most significant peaks were analyzed using THEME (16) to 
identify the enriched motif within this set.  
 
3.4 Results 
 
3.4.1  Determining the optimal BrdU dose for lymphoblastoid cells 
 
The first step in using the proliferation assay (described in Chapter 2) to obtain the dose-response 
curve of a cell line to a particular DNA damaging agent was to establish the optimal BrdU 
concentration for the cell lines being tested. This optimal concentration is defined as the 
concentration of BrdU that quenches Hoechst fluorescence of cells in the G1 phase of the cell 
cycle by one half after cells complete one doubling in the presence of BrdU (17-19). Half-
quenching of Hoechst fluorescence in the first cell cycle is necessary for optimal resolution of 
cells that have divided once, twice or thrice in the presence of BrdU.  
 
The optimization was performed in the lymphoblastoid cell line TK6 with the assumption that all 
lymphoblastoid cell lines would require similar BrdU concentrations to quench G1 Hoechst 
fluorescence by half. A range of BrdU doses between 0-100 µM was tested by growing TK6 
cells in the presence of BrdU for a little more than one doubling time (16 hours). Figure 3.1 
shows the flow cytometry plots obtained for the four BrdU concentrations tested. As is seen in 
the figure, 45µM BrdU was enough to quench Hoechst fluorescence by almost half (from ~90K 
to ~50K) and any further increase in the BrdU concentration did not significantly increase 
quenching. Moreover, doses of BrdU lower than 45µM did not yield enough Hoechst quenching. 
Therefore, 45µM BrdU was defined as the optimal concentration for the panel of 24 cell lines. 
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Flow cytometry scatter plots of PI fluorescence vs. hoechst fluorescence showing hoechst 
quenching for various doses of BrdU. The difference in hoechst fluorescence between G1 cells 
of the first (G1’) and second cell cycle (G1’’) is marked along the x-axis.  
Figure 3.1: Determining the optimal BrdU concentration for lymphoblastoid cell lines 
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3.4.2 Cell lines show no G2/M arrest after BrdU addition 
 
Although most diploid cells show no cell cycle effects from short term BrdU incorporation 
(20,21), in some cell types, BrdU is known to induce a G2/M arrest (22). Therefore, a fraction of 
the twenty-four cell lines were tested to see whether lymphoblastoid cell lines undergo a G2/M 
arrest when grown in 45µM BrdU. For this experiment, cells were grown in the presence of 
BrdU for 48 hours. At various time intervals during the BrdU incubation, cells were collected, 
fixed in 100% ethanol, stained with propidium iodide (as described in the Materials and Methods 
section) and analyzed by flow-cytometry to obtain cell cycle profiles. Figure 3.2 to Figure 3.7 
show the cell cycle profiles, fraction of cells in G1 and G2 over time, and the growth of cells in 
the presence of BrdU for the cell lines tested. These show that no discernible G2/M arrest or 
growth retardation is seen in these lymphoblastoid cell lines grown for a 48 hours in the presence 
of BrdU. 
 
3.4.3 The genetically varied panel of cell lines show a wide range of 
sensitivities to BCNU 
 
With the optimal BrdU concentration defined as 45µM and the knowledge that this dose did not 
induce a G2/M arrest in the lymphoblastoid cell lines, the panel of cell lines were ready to be 
screened for BCNU sensitivity. It is important to note that the multi-well proliferation assay used 
to ascertain BCNU sensitivity is dependent on the doubling times of the cell lines being assayed. 
Based on previously determined doubling times (Samson lab, unpublished data), the panel of cell 
lines was divided into four sub-groups. The four sub-groups are shown in Table 3.1, 
accompanied by the approximate doubling times defined for each group. 
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Cell cycle profiles for cells grown in the absence (top panel) or presence (middle panel) of 45µM BrdU 
for 0, 25 and 48 hours. The bottom, left panel shows fraction of cells in G1 (squares) and G2 (circles) for 
cells grown with 0 (open) or 45µM (filled) BrdU. The bottom, right panel shows cell growth for cells 
grown in 0 (open) or 45µM (filled) BrdU. 
 
Figure 3.2: Checking for BrdU dependant G2/M arrest in Cell line 6
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Figure 3.3: Checking for BrdU dependant G2/M arrest in Cell line 14 
Cell cycle profiles for cells grown in the absence (top panel) or presence (middle panel) of 45µM BrdU 
for 0, 25 and 48 hours. The bottom, left panel shows fraction of cells in G1 (squares) and G2 (circles) for 
cells grown with 0 (open) or 45µM (filled) BrdU. The bottom, right panel shows cell growth for cells 
grown in 0 (open) or 45µM (filled) BrdU.
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Figure 3.4: Checking for BrdU dependant G2/M arrest in Cell line 16 
Cell cycle profiles for cells grown in the absence (top panel) or presence (middle panel) of 45µM BrdU 
for 0, 25 and 48 hours. The bottom, left panel shows fraction of cells in G1 (squares) and G2 (circles) for 
cells grown with 0 (open) or 45µM (filled) BrdU. The bottom, right panel shows cell growth for cells 
grown in 0 (open) or 45µM (filled) BrdU. 
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Cell cycle profiles for cells grown in the absence (top panel) or presence (middle panel) of 45µM BrdU 
for 0, 25 and 48 hours. The bottom, left panel shows fraction of cells in G1 (squares) and G2 (circles) for 
cells grown with 0 (open) or 45µM (filled) BrdU. The bottom, right panel shows cell growth for cells 
grown in 0 (open) or 45µM (filled) BrdU. 
 
Figure 3.5: Checking for BrdU dependant G2/M arrest in Cell line 21
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Figure 3.6: Checking for BrdU dependant G2/M arrest in Cell line 22 
Cell cycle profiles for cells grown in the absence (top panel) or presence (middle panel) of 45µM BrdU 
for 0, 25 and 48 hours. The bottom, left panel shows fraction of cells in G1 (squares) and G2 (circles) for 
cells grown with 0 (open) or 45µM (filled) BrdU. The bottom, right panel shows cell growth for cells 
grown in 0 (open) or 45µM (filled) BrdU
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 Figure 3.7: Checking for BrdU dependant G2/M arrest in Cell line 24 
Cell cycle profiles for cells grown in the absence (top panel) or presence (middle panel) of 45µM BrdU 
for 0, 25 and 48 hours. The bottom, left panel shows fraction of cells in G1 (squares) and G2 (circles) for 
cells grown with 0 (open) or 45µM (filled) BrdU. The bottom, right panel shows cell growth for cells 
grown in 0 (open) or 45µM (filled) BrdU 
Chapter 3: Transcriptional Response to BCNU 
 
       
   
83 
Table 3.1: The partition of the panel of 24 cell lines based on their doubling times 
 
Cell Line  CCR Catalog No. 
Normal doubling 
time (h)  Group No. 
Approx. 
doubling time 
(h) 
8  GM15510  17  1  18 
22  GM15324  19  1  18 
21  GM15268  20  2  22 
20  GM15242  20  2  22 
16  GM15072  21  2  22 
24  GM15061  21  2  22 
6  GM15224  22  2  22 
14  GM15038  22  2  22 
1  GM15029  22  2  22 
17  GM15144  22  2  22 
3  GM15215  23  2  22 
5  GM15245  24  2  22 
15  GM15056  24  2  22 
23  GM15386  24  2  22 
12  GM15385  25  3  27 
13  GM15590  25  3  27 
9  GM15213  26  3  27 
19  GM15226  27  3  27 
7  GM15236  27  3  27 
2  GM13036  28  3  27 
4  GM15223  30  3  27 
11  GM15227  30  3  27 
18  GM15216  35  4  37 
10  GM15221  40  4  37 
 
The 24 cell lines were ordered based on their normal doubling time, divided into four groups. Cell lines in 
each group were assayed based on the approximate doubling time for the group. 
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Based on preliminary experiments, the doses chosen for BCNU treatment were 0, 10, 20, 40, 60 
and 80 µM BCNU. Cell lines with similar doubling times that belonged to the same sub-group 
were assayed on one 96-well plate. The survival curves were obtained using the proliferation 
assay (see Materials and Methods). Once the data was collected, all flow cytometry data was 
analyzed using FlowJo (TreeStar Inc.) as described in the Chapter 2. Gates were drawn 
appropriately and the percentage of proliferating cells was calculated to obtain survival curves 
for the 24 cell lines. The survival curves obtained in this manner for the panel of 24 cell lines are 
shown in Figure 3.8.   
 
From Figure 3.8, one can see that there is a wide range of sensitivities for the panel of cell lines 
exposed to BCNU. The panel of genetically varied cell lines was also previously shown to have a 
wide range of sensitivities to other alkylating agents MNNG (23) and MMS (unpublished data). 
To identify any correlation between the sensitivities of the cell lines for the three agents, a 
correlation coefficient was calculated between the three possible pairs of treatments: (BCNU, 
MMS), (BCNU, MNNG) and (MNNG, MMS). As seen in Figure 3.9 , the correlation between 
the sensitivity values for the three DNA damaging agents is weak, (R2= 0.15, 0.28 and 0.23 
respectively) thus suggesting that the factors that affect the sensitivity of the cell lines to the 
three agents are different. 
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Figure 3.8: Survival curves for the 24 cell lines after BCNU treatment
 
 
 
Survival curves for the panel of 24 genetically varied cell lines for BCNU doses of 0, 10, 20 .40, 60 and 80 
µM. Graphs were obtained using the proliferation assay described in Chapter 2 
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The R2 for correlation between the sensitivity of the cell lines for the MMS (0.4mM), MNNG (0.5μg/ml) 
and BCNU (40μM) was calculated for each of the pairs (BCNU, MMS), (BCNU,MNNG) and (MNNG, 
MMS). The values for R2 obtained are shown on each plot. 
Figure 3.9: Correlation between sensitivities of the 24 cell lines to MMS, MNNG and BCNU
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To identify genes whose basal expression values correlate well with BCNU sensitivity, and 
possibly affect the BCNU sensitivity of the cell lines, previously obtained basal expression for 
the twenty four cell lines from (23) was used. These basal gene expression values were 
correlated with the BCNU sensitivity values of the cell lines at the 40μM dose. Those genes that 
had an r > 0.6 or r < -0.6 with a p-value < 0.05 of correlation were selected. 123 probe-sets 
corresponding to 94 genes passed these criteria and are shown in Table 3.2 and a heat-map 
representation of their expression values is shown in Figure 3.10A. Of these genes, only one 
gene, O6-methylguanine DNA methyltransferase (MGMT) is positively correlated with BCNU 
sensitivity. This is reassuring since MGMT is known to remove the O6-chloroethyl adduct 
generated by BCNU and confer resistance to BCNU treatment in the clinic. All of the other 
genes included within this list are negatively correlated with BCNU resistance and most have not 
yet been associated with BCNU sensitivity or resistance. Gene ontology enrichment (see 
Materials and Methods) shows that the 94 genes are enriched for molecular processes involved in 
protein catabolism (see Figure 3.10B), a process yet to be studied in the context of BCNU 
exposure. 
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(A) Heat-map of 123 probesets (corresponding to 94 genes) with high positive or negative correlation 
with BCNU sensitivity (r > 0.6 or r < -0.6 with p-value < 0.05) ordered according to their correlation. The 
top-most gene is MGMT and is the only positively correlated gene;  (B) Gene ontology enrichment within 
the set of 94 genes obtained using GO-FAT from DAVID (v7.6) 
Figure 3.10: Genes whose basal expression correlates with BCNU sensitivity
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Table 3.2: 123 probesets with high positive or negative correlation to BCNU sensitivity 
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Table 3.2 (contd.) 
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Table 3.2 (contd.) 
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3.4.4 Cell cycle profiles for cell lines with extreme BCNU 
sensitivity/resistance define the time frame for microarray 
measurements 
 
From the wide range of sensitivities observed in the panel of 24 cell liens after BCNU treatment, 
we chose the two cell lines that were most sensitive to BCNU (cell lines 4 and 5) and the two 
that were most resistant (cell lines 13 and 16) for further analyses. Although the proliferation 
assay gives a measure of how sensitive a cell line is to BCNU, it provides no information about 
the time frame within which key cellular decisions are made after BCNU treatment. To better 
gauge the duration after DNA damage within which interesting transcriptional changes might 
occur, we measured some phenotypic properties of the four cell lines to gain insight into the 
changes that occur in these cell lines after BCNU treatment. Informative time points at which to 
measure transcripts were identified. We also chose to use 40µM BCNU for all of the subsequent 
experiments since this dose had only a slight effect on the resistant cell lines, while inducing 
significant death in the sensitive cell lines, but not so much death that it would be impossible to 
harvest cells for RNA isolation.   
 
One well studied property of cells after DNA damage is the initiation of cell cycle checkpoints in 
the presence of damage. BCNU has previously been shown to induce late S or G2/M arrest in 
glioblastoma cell lines (24). We reasoned that if such an arrest occurs with the set of four cell 
lines used here, the time points prior to initiation of the cell cycle arrest, and all the way up to 
resolution of the arrest or initiation of cell death would yield informative transcriptional data.  
 
Cell cycle profiles measured at various time points after DNA damage provide information on 
whether cell cycle arrest occurs in treated versus mock-treated cells, how long after treatment 
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such an arrest occurs, the duration and nature of the arrest, and whether cells are able to resolve 
the arrest and resume normal cell cycle progression. The final piece of information that can be 
obtained from cell cycle profile measurements is the time, post-treatment, when a sub-G1 
population becomes visible in the sensitive cell lines, thus indicating the possible time point at 
which DNA fragmentation begins. 
 
Therefore, with the goal of identifying time points for global transcriptional profiling, cell cycle 
profiles were measured for the four cell lines after BCNU treatment. The four cell lines were 
treated with BCNU (see Materials and Methods). Cells were collected at multiple time-points all 
the way up to 96 hours post treatment for cell cycle profile measurements by flow cytometry (as 
described in the Methods section).  
 
Figure 3.11 and Figure 3.12 show cell cycle profiles of the sensitive cell lines 4 and 5 
respectively at multiple time-points post BCNU treatment. These cell cycle profiles four 
important features - i) there is an initial accumulation of cells in the S-phase of the cell cycle 
slightly visible at 12 hours and more prominent at 24 and 36 hours post BCNU treatment; ii) 
there is slow progression of cells through S-phase towards 4N DNA content all the way up to the 
48 hour time point, accompanied by a decrease in the G1 population;  iii) there is an increase in 
the sub-G1 population beginning at 24 hours for the most sensitive cell line (cell line 4) and at 
48hours for the other sensitive cell line 5, and increasing all the way up to the 96 hour time point; 
iv) the accumulation of cells in G2/M is minimal in the sensitive cells. In contrast to the sensitive 
cell lines, the cell cycle profiles of the resistant cell lines16 and 13 (seen in Figure 3.13 and 
Figure 3.14) show no obvious differences between treated and mock-treated samples.  
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Cell cycle profiles for cell line 4 either mock-treated (top panel) or BCNU treated (middle panel) at 12, 24 
and 48 hours.  The bottom panel shows quantification of  sub-G1, G1, S and G2 cell cycle phases at each 
time point for mock-treated (open) and BCNU treated (filled) samples. 
  
Figure 3.11: Cell cycle progression of the BCNU sensitive cell line 4  
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Figure 3.12: Cell cycle progression of the BCNU sensitive cell line 5 
Cell cycle profiles for cell line 5 either mock-treated (top panel) or BCNU treated (middle panel) at 12, 24 
and 48 hours.  The bottom panel shows quantification of  sub-G1, G1, S and G2 cell cycle phases at each 
time point for mock-treated (open) and BCNU treated (filled) samples. 
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Figure 3.13: Cell cycle progression of the BCNU resistant cell line 16 
Cell cycle profiles for cell line 13 either mock-treated (top panel) or BCNU treated (middle panel) at 12, 
24 and 48 hours. The bottom panel shows quantification of sub-G1, G1, S and G2 cell cycle phases at 
each time point for control (open) and BCNU treated (filled) samples. 
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Cell cycle profiles for cell line 13 either mock-treated (top panel) or BCNU treated (middle panel) at 12, 
24 and 48 hours. The bottom panel shows quantification of sub-G1, G1, S and G2 cell cycle phases at 
each time point for control (open) and BCNU treated (filled) samples. 
Figure 3.14: Cell cycle progression of the BCNU resistant cell line 13 
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3.4.5 Viable cell number measurements for BCNU sensitive/resistant cell 
lines show growth inhibition for sensitive cell lines but not resistant 
cell lines 
 
To complement the cell cycle profile measurements, viable cell numbers were measured by 
trypan blue exclusion to determine the relative growth rates between treated and mock-treated 
samples. Figure 3.15 shows the viable cell numbers for the four cell lines. The figure shows that 
the two sensitive cell lines show strong growth inhibition after BCNU exposure as compared to 
mock-treated samples. In contrast, the viable cell measurements of the resistant cell lines only 
showed a slight lag in cell growth. The fact that the cell cycle profile measurements of the 
resistant cell lines showed no discernible stalling of cells in any one phase of the cell cycle 
suggests that the lag in cell growth in resistant cell lines is not due to a strong cell cycle arrest but 
could be due to a fleeting arrest that was either missed or undetectable by the assay used.  
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Cell density as measured by trypan blue exclusion for the two sensitive cell lines (left panels) and two 
resistant cell lines (right panels) for control (open) and BCNU treated (filled) samples. All cell lines were 
treated with 40µM BCNU 
Figure 3.15:  Growth inhibition of cell lines showing extreme BCNU sensitivity/resistance 
Chapter 3: Transcriptional Response to BCNU 
 
       
   
100 
3.4.6 Designing and generating a multi-dimensional transcriptional data set 
 
Taken together, the cell cycle profile and viability measurements for the two most sensitive and 
two most resistant cell lines defined the time points at which global transcription profiles should 
be measured. The first signs of S-phase accumulation occurred in sensitive cell lines at the 12 
hour time-point. However, transcription programs take time to be activated in order to change the 
state of the cell. Moreover, any transcript changes that could explain the slight lag in growth of 
the resistant cell lines would most likely be observed early in the time course. Therefore, early 
time points including 4 hours, 8 hours and 12 hours were chosen to capture any transcript 
changes that might be involved in the accumulation of sensitive cells in the S-phase of the cell 
cycle and the slower growth of the resistant cell lines. As observed from the late increase in the 
sub-G1 population in sensitive cell lines, cell death was a late event, with an increase in the sub-
G1 population only seen after 24-48 hours. Therefore, additional late time-points were measured, 
including 24, 36, 48 and 72 hours to capture transcripts that might provide insight into the 
observed cell death.  
 
Once the time points for microarray measurements were determined, there was one more 
decision to be made regarding the design of the experiment. Since the BCNU treatment involves 
an hour-long incubation of cells in serum-free media, we anticipated that serum starvation would 
induce a stress response as was observed in (25). It was therefore important to measure transcript 
changes in mock-treated samples that also underwent an hour-long incubation in serum-free 
media minus BCNU, to ensure correct identification of DNA damage related transcriptional 
changes. Therefore, transcript changes were measured in both mock-treated and BCNU treated 
samples to discern the BCNU treatment related expression changes. 
Chapter 3: Transcriptional Response to BCNU 
 
       
   
101 
With all the parameters, time points and conditions determined, time-series experiments were 
performed. Cell lines 4, 5, 13 and 16 were treated with 40µM BCNU as described in the 
Materials and Methods section. Cells were collected at 0, 4, 8, 12, 24, 36, 48 and 72 hours post 
BCNU treatment and RNA was isolated. The RNA was tested for integrity and hybridized onto 
Affymetrix HG-U133 plus 2.0 chips (see Materials and Methods).  
 
3.4.7 Exploring the transcriptional data space 
 
As a first step towards understanding the transcriptional changes after BCNU treatment, 
approximately 10,000 probe-sets that varied over time, treatment or cell line were visualized. 
These probe-sets are shown in Figure 3.16 and reveal some interesting properties of the data set. 
Many probe-sets that show induction or repression in treated samples relative to the 0h time-
point also show similar induction or repression in mock-treated samples over time (examples are 
highlighted in the box). Therefore gene expression changes are seen in both mock-treated and 
treated samples showing that these changes are not necessarily BCNU dependent.  
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 The heat-map shows probe-set values (rows) for each array (column). Values are log2 ratios as compared 
to the 0h time-point. Mock-treated samples are on the left and treated samples are on the right. The black 
box marks examples of probe-sets that show expression changes in both mock-treated and treated samples 
over time.  
Figure 3.16: Transcripts that vary with time, cell line and treatment 
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One reason for such varying gene expression in mock-treated samples might be the inherent 
expression changes that occur as cells progress from the early log-phase of growth to mid-log 
and finally to the stationary phase of growth (26).  Other studies have shown that gene-
expression changes with change in proliferation rate, which changes as cells move along the 
growth curve (27). In addition to growth-rate induced gene-expression changes, there is another 
possible cause for the observed gene expression changes within mock-treated samples in this 
particular experiment, namely serum-starvation. Even short exposure to serum-free media has 
been shown to induce transcriptional change in certain cell types (25). Regardless of the cause of 
gene expression changes over time in the mock-treated samples, we know that these changes are 
not related to or in response to BCNU treatment. Therefore, we took the approach of identifying 
transcripts that are differentially induced or repressed in the treated versus mock-treated samples 
over time to obtain true BCNU-induced transcriptional changes. 
  
A second observation from visualizing the data set in Figure 3.16 is that gene induction and 
repression patterns even in the mock-treated samples differ between the two sensitive cell lines 
(compare the first and second columns within the box in Figure 3.16). Therefore, there was no 
guarantee that the two sensitive cell lines would have similar gene expression responses to 
BCNU treatment. However, if we were to identify such a set of genes that behaved similarly in 
the two sensitive cell lines but differently between sensitive and resistant cell lines, this signature 
could be a strong indicator of key transcriptional changes that affect cell sensitivity to BCNU.  
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3.4.8 Identifying a general transcriptional signature for cell death/survival 
after DNA damage 
 
From our data set, we wanted to identify genes that were induced or repressed differentially 
between sensitive and resistant cell lines but similarly in the two sensitive cell lines, or in the two 
resistant cell lines upon BCNU treatment. For example genes induced after BCNU treatment to a 
greater extent in the two sensitive cell lines but to a lesser extent in the resistant cell lines might 
help us describe transcriptional programs that are induced when cells are destined to die after 
DNA damage. Conversely, genes that are induced to a greater extent in treated resistant cell lines 
as compared to the sensitive cell lines, might give us insight into any transcripts that protect cells 
against DNA damaging agents. Moreover, requiring gene expression changes to follow similar 
expression patterns in the two sensitive or two resistant cell lines eliminates any cell line specific 
gene expression changes. 
 
In our data set, each gene expression value is associated with three discrete variables – treatment 
(0 or 40 µM BCNU), time (0, 4, 8, 12, 24, 36, 48, 72 hours) and sensitivity (sensitive or resistant 
cell line). Using 3-way ANOVA in MATLAB, genes that were significantly different in the 
treatment and sensitivity variables either at all time-points or at a subset of time-points were 
identified (details of the analysis are described in the Materials and Methods section). This 
yielded 984 probe-sets representing 706 genes that were differentially induced or repressed 
between the sensitive and resistant cell lines. Within this set of 984 probe-sets, differential gene 
expression values between sensitive and resistant cell lines at any of the eight time points ranged 
from 4.2 to -1.7 when calculated as a log2 ratio of sensitive to resistant gene expression value. 
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3.4.9 Visualizing the DNA damage induced transcriptional signature 
 
As a first step towards understanding the biological meaning and relevance of the 984 probe-sets 
extracted using ANOVA, the probe-sets were clustered to identify striking expression patterns 
present within the gene set. A heat-map representing the gene set clustered using hierarchical 
clustering (GenePattern suite, Broad Institute) is shown in Figure 3.17.  
 
The heat-map shows that the 984 probe-sets (representing 706 genes) can be divided into two 
groups – those that are induced, and those that are repressed to a greater extent in the sensitive 
treated cells compared to the resistant treated cells. The concerted induction and repression of 
these genes more so in the two sensitive cell lines as compared to the two resistant cell lines 
suggests that these genes are most likely relevant for the decision to die rather than survive after 
DNA damage. To further investigate the biological context of these 706 genes and the cellular 
pathways they are involved in, network analysis was performed on the selected gene sets. 
 
3.4.10  Network and canonical pathway analyses reveal the biological 
relevance of the transcriptional signature 
 
The network connectivity within the set of 984 probe-sets was obtained through the use of 
Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com). Out of the 706 genes, 
507 were eligible for functional and pathway analysis and 295 were eligible for network analysis 
(only those genes and interactions that were experimentally identified in human cell lines were 
considered eligible). The top four significant networks are involved in cell death, cell cycle, 
cancer and cell growth proliferation (Figure 3.18A).  
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Each row is a probe-set, and each column one time-point. Values are log ratios as compared to the 0h 
time-point. Mock-treated and treated samples for each cell-line are shown next to each other. 
Figure 3.17: Hierarchical clustering of the BCNU transcriptional signature  
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Focus molecules, indicated in bold, are the molecules in our gene set also present in the network. 
These four networks are interconnected and form one large network containing 273 of the 295 
network eligible genes (Figure 3.18B). What this shows is that a majority of the network eligible 
genes from our signature set form interconnected signaling and interaction modules that are 
involved in cell death, cell cycle, growth and proliferation.  
 
Looking at sub-networks within the larger network obtained from our gene set, we see examples 
of signaling modules that could provide some insight into the pathways utilized by the sensitive 
cell lines in the response to BCNU treatment. Figure 3.19 shows an example of a sub-network 
containing the tumor suppressor and DNA damage response modulator p53 as the hub node 
regulating targets from our selected gene set that are involved in DNA replication, repair and cell 
cycle. Identifying p53 related signaling modules and the pathways and networks that control cell 
cycle, cell death and proliferation increases our confidence in the selected gene set as a DNA 
damage response gene set and provides some insight into possible signaling modules involved in 
cell death/survival decisions after BCNU treatment. 
 
In addition to network analyses, canonical pathways that were enriched within our data set were 
identified. Canonical pathways, as defined by ingenuity, are predefined and well studied 
pathways within the database. Figure 3.20 shows the canonical pathways that are enriched within 
our transcriptional signature. p53 signaling, G2/M arrest, aryl-hydrocarbon receptor signaling, 
cell cycle regulation and mitotic roles of Polo-like kinase are the most significantly enriched 
canonical pathways within the entire gene set. We infer that the transcriptional signature genes 
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are involved in key DNA damage response pathways with the exception of the aryl-hydrocarbon 
pathway that has not yet been implicated in DNA damage response.  
 
Both the network and canonical pathway analyses confirm that among the set of 706 genes 
identified from the ANOVA analysis, a large fraction are meaningful in the response of a cells to 
a DNA damaging agent and that they contribute to cell death, survival and cell cycle control. 
However, because these analyses were performed with the entire gene set consisting of both up-
regulated and down-regulated genes, the resulting networks were complex and hard to 
comprehend. Instead, if it were the case that the up-regulated or down-regulated genes were 
involved in functionally separate pathways, the system and transcriptional response might be 
easier to understand. 
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Figure 3.18: Network connectivity of the transcriptional signature 
 
A) Top four networks obtained from the 295 network eligible genes show enrichment of cell death, cell 
cycle and DNA repair functions, Focus molecules (bold) and up-regulated (red) or down-regulated 
(green) molecules are marked; B) The four top networks are interconnected and contain 273 of the 295 
genes 
Chapter 3: Transcriptional Response to BCNU 
 
       
   
110 
Figure 3.19: A p53-centric network with DNA replication, repair and cell cycle genes 
 
A sub-network within the large interconnected network showing a p53-centric network consisting of up-
regulated (red) genes mainly involved in DNA repair and the down-regulated genes (green) mainly 
involved in DNA replication and cell cycle.  
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Canonical pathways defined in the Ingenuity database that are enriched within the 507 eligible genes from 
the transcriptional signature set.  
 
Figure 3.20: Canonical pathways significantly enriched in the transcriptional signature 
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3.4.11 The transcriptional signature can be partitioned into two 
functionally meaningful subsets 
 
Gene ontology enrichment was performed separately on the set of up-regulated and down-
regulated genes using the Database for Annotation, Visualization and Integrated Discovery 
(DAVID v6.7) as described in the methods section.  The Gene Ontology (GO) biological 
processes enriched within the up-regulated and down-regulated genes in the transcriptional 
signature are shown in Figure 3.21. The GO enrichment for the up-regulated genes specifically 
identified apoptotic cell death rather than any other cell death mechanism. Similarly, the 
repressed subset of genes showed enrichment in genes involved in the mitotic phase of the cell 
cycle.  
 
Network analyses were performed separately for the induced and repressed gene sets. The 
resulting canonical pathway enrichment is shown in Figure 3.22. p53 signaling is the most 
significantly enriched canonical pathway for the induced genes, followed by enrichment in 
various cancer signaling pathways. Cell cycle as well as protein and RNA metabolism related 
canonical pathways are enriched in the repressed genes. It is interesting to note that the canonical 
pathways enriched within the combined set of up and down-regulated genes were distributed 
among, rather than appearing in both the induced and repressed gene sets. 
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Figure 3.21: Gene Ontology enrichment of the up-regulated and down-regulated gene sets 
 
GO enrichment for the up- and down-regulated genes from the transcriptional signature performed using 
DAVID(v.6.7) and the standard GO-FAT algorithm which highlights lower level terms present within the 
data set.. 
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Figure 3.22: Canonical pathway enrichment of  the up-regulated and down-regulated gene sets 
 
Canonical pathway enrichment performed separately on the up-regulated and down-regulated genes from 
the transcriptional signature.  
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Two of the top networks obtained for the up-regulated genes are shown in Figure 3.23. The top 
function associated with these networks was cell death (p < 5x10-10) in concordance with GO 
enrichment for the up-regulated genes. The nodes within the sub-networks shown in Figure 3.23 
that are annotated in the Ingenuity database as being involved in cell death are highlighted in 
blue. These sub-networks show that 35/48 focus molecules in Figure 3.23A and 16/31 focus 
molecules in Figure 3.23B are involved in cell death. The network shown in Figure 3.23A is also 
enriched for cell growth and proliferation (p < 5x10-10; 26/48 focus molecules) and cellular 
development (p < 5x10-10; 23/48 focus molecules). For the network shown in Figure 3.23B no 
other functions besides cell death are enriched past the significance cutoff. In these networks, 
nodes are colored based on their expression value in cell line 4, with red nodes showing genes 
that are induced, with color intensity representing expression value. (Table 3.3 corresponds to the 
networks shown in Figure 3.23) 
 
Figure 3.24 shows two of the top sub-networks obtained for the down-regulated genes. These 
two sub-networks are significantly enriched in cell cycle processes (p < 5X10-10), again in 
concordance with GO enrichment. Nodes that are associated with cell cycle functions in the 
Ingenuity database are highlighted in blue. There are18/40 focus molecules in Figure 3.24A and 
13/33 focus molecules in Figure 3.24B that are involved in cell cycle functions. The network in 
Figure 3.24B is also enriched for cellular assembly and organization (7/33 focus molecules), and 
DNA replication, recombination, and repair (7/33 focus molecules). Again the network is 
colored based on the expression values of the nodes in cell line 4.  (Table 3.4 corresponds to the 
networks shown in Figure 3.24)  
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Gene Ontology enrichment, network connectivity and canonical pathway analysis highlight the 
fact that the transcriptional signature identified here can be split into two coherent groups; a 
group of genes differentially up-regulated in BCNU treated sensitive cell lines compared to 
resistant cell lines that are suggested to be involved in cell death functions and p53 signaling; and 
a second group of genes differentially down-regulated in the sensitive cell lines compared to the 
resistant cell lines that are suggested to be involved in cell cycle pathways. 
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Nodes highlighted in blue are annotated in the ingenuity database as being involved in cell death. 
Members of the up-regulated set are colored based on their expression value, red indicating up-regulation, 
and the intensity indicating expression value. The top network (A) and the second network (B) are shown 
(Legend same as for Figure 3.19)  
Figure 3.23: Top networks for the set of  up-regulated genes are involved in cell death 
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 Focus molecules are in bold. Significantly (p < 5x10-10) enriched functions are labeled. 
Table 3.3: Molecules in network A and B from Figure 3.23 for the up-regulated gene set 
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Nodes highlighted in blue are annotated in the Ingenuity database as being involved in cell cycle. 
Members of the down-regulated set are colored based on their expression value, green indicating down-
regulation, and the intensity indicating expression value. The top network (A) and the second network (B) 
are shown (Legend same as for Figure 3.19) 
Figure 3.24: Top two networks for the down-regulated genes are involved in cell cycle 
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Focus molecules are in bold. Significantly (p < 5x10-10) enriched functions are labeled. 
 
Table 3.4: Molecules in network A and B from Figure 3.24 for the down-regulated gene set 
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3.4.12 BCNU sensitive cell lines induce cell death by apoptosis 
 
The functional enrichment of the transcriptional signature showed a strong induction of genes 
involved in apoptosis in the sensitive cell lines 4 and 5 upon BCNU treatment. Previous studies 
showed that BCNU induces growth inhibition and cell killing in glioblastoma and other 
cancerous cell lines (24,28,29). The few studies that explored BCNU induced cell death 
mechanisms in human cells showed that some glioblastoma cell lines induce apoptosis upon 
BCNU treatment (30-32) whereas in other cases BCNU had a caspase inhibitory activity (33). 
Additionally, in the lymphoblastoid cell line TK6, BCNU was seen to induce apoptosis (34).  
 
Although we knew that BCNU induced strong growth inhibition in cell lines 4 and 5 as seen 
from the proliferation assay and viability measurements (Figure 3.8 and Figure 3.15), we did not 
know the mechanisms of cell death induction in these particular cell lines. However, the 
induction of apoptotic genes within out transcription data, combined with previous evidence that 
BCNU induced cell death by apoptosis in TK6 cell lines suggested that the sensitive cell lines 4 
and 5 most likely induce apoptosis when exposed to BCNU.   
 
To confirm this, we used the AnnexinV/7AAD assay to measure cell death in cell lines 4, 5, 16 
and 13 after BCNU treatment. During early apoptosis, phosphatidylserine (PS), usually located 
in the cytoplasmic side of the cell membrane, is flipped and exposed on the external surface of 
the cell (35). AnnexinV can bind PS with high affinity (36). Therefore, AnnexinV tagged with a 
fluorophore (such as phycoerythrin –PE) can be used to detect cells that have initiated apoptosis 
by flow cytometry. However, PE-AnnexinV can also permeate and stain cells that are already 
dead and that have compromised cell membrane integrity. Therefore, to distinguish AnnexinV 
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staining in early apoptotic versus dead cells, an additional dye, 7AAD, that only stains dead cells 
with compromised cell membranes is used. This yields flow cytometry plots as seen in Figure 
3.25 with cells falling within one of four quadrants – i) the lower left quadrant contains 
AnnexinV and 7AAD negative live cells with intact cell membranes and PS on the cytoplasmic 
side of the membrane; ii) the lower right quadrant contains AnnexinV positive and 7AAD 
negative early apoptotic cells with exposed PS but intact membranes; iii) the upper right 
quadrant contains AnnexinV and 7AAD positive dead cells that have lost cell membrane 
integrity and iv) the upper left quadrant contains AnnexinV negative and 7AAD positive cells 
that induce cell death by mechanisms other than apoptosis, or dead cells that have lost all PS. 
 
The four cell lines with extreme BCNU sensitivity/resistance were treated with 40µM BCNU as 
described in the methods section. At each of 12, 24, 48 and 72 hours, cells were collected, 
incubated with 7AAD and PE-AnnexinV (see Materials and Methods) and immediately analyzed 
by flow cytometry. Figure 3.25 shows an example of plots obtained for the four cell lines at 
48hours post BCNU treatment. We see that there is a visible increase in the early apoptotic 
population after BCNU treatment in the two sensitive cells lines as compared to the resistant 
cells lines. Figure 3.26 shows the quantified data from all time-points for the four quadrants. The 
data show a significant increase, over time, in the early apoptotic and dead cell populations and a 
significant decrease in the live cell population for the two sensitive cell lines. Note that we do not 
see direct migration of cells from live cell quadrant to the upper left quadrant thus confirming 
that the major path to cell death after BCNU treatment occurs through apoptosis. Another point 
to note is that among the two sensitive cell liens, the extent of apoptosis and cell death is greater 
in the most sensitive cell line 4 and lesser in the cell line 5, as is expected from the survival data. 
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Flow cytometry scatter plots of Annexin V vs. 7AAD for cell lines 4, 5, 16 and 13 at 48h post BCNU 
treatment. The top panel shows mock-treated samples and the bottom panel shows BCNU treated 
samples. The four quadrants are marked as live, apoptotic, dead and necrotic as described in the text.  
Figure 3.25: Annexin V/ 7AAD plots for the four cell lines at 48h post BCNU treatment 
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Plots of live, apoptotic, dead and necrotic populations as quantified from flow cytometry scatter plots at 0, 
12, 24, 48 and 72 hours post BCNU treatment.  
Figure 3.26: Quantification from AnnexinV/7AAD plots at multiple times post BCNU treatment 
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3.4.13 BCNU sensitive cell lines stall mitotic entry 
 
Cell cycle profiles obtained from initial experiments (Figure 3.11 and Figure 3.11) had shown 
sensitive cells accumulating in late S more so than in the G2 phase of the cell cycle after BCNU 
treatment. Genes involved in mitosis are known to slowly accumulate during S phase of the cell 
cycle and peak in the G2 phase of the cell cycle immediately prior to mitosis. Therefore, 
although treated cells had a higher fraction of S-phase cells, and at least an equal fraction of G2 
cells as compared to mock-treated samples, we observed a decrease in the mitotic genes. This 
suggested that BCNU treated cells failed to enter mitosis.  
 
To confirm that BCNU treated cells failed to enter mitosis after BCNU treatment, we used flow 
cytometry based detection of histone H3 phosphorylation as a marker for mitotic cells (37). 
Histone H3 is phosphorylated during early mitosis (38). Therefore using an Alexafluor 
conjugated antibody against phosphorylated histone H3, we can detect the fraction of cells 
undergoing mitosis after BCNU treatment by flow cytometry. For this assay, cells were treated 
with 40µM BCNU, collected at 12, 24, 48 and 72 hours post BCNU treatment and fixed in 
paraformaldehyde and stored at -200 C. Before analysis by flow cytometry, cells were incubated 
with anti-phosphorylated Histone H3 antibody and propidium iodide (see Materials and 
Methods) and analyzed by flow cytometry. 
 
Figure 3.27 shows a snap shot of mitotic cells at 48hours post BCNU treatment where the mitotic 
population is almost completely absent in the sensitive cell lines but not in the resistant cell lines 
compared to mock-treated samples. Figure 3.28 shows the quantified mitotic fraction over time 
for the four cell lines. The drop in the mitotic population seen in sensitive cell lines occurs prior 
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to the 12 hour time point and remained low up to the 72 hour time-point. However no significant 
changes were seen in the resistant cell lines. These results show that the transcriptional down-
regulation of mitotic genes correlates with a concomitant decrease in the mitotic population in 
treated, sensitive cell lines. 
 
3.4.14 p53 is activated to a greater extent in sensitive cell lines as compared    
to resistant cell lines 
 
Canonical pathway analysis showed that the gene set that was induced in BCNU treated, 
sensitive cell lines was enriched for p53 signaling. p53 is known to be activated after BCNU 
treatment in glioblastoma cell lines and p53 status affects the sensitivity of cells to BCNU 
(24,39,40). The standard mode of p53 activation involves its phosphorylation and accumulation 
which we expected to see happening to a greater extent in the two sensitive cell lines than in the 
resistant cell lines. To test this, we used immunoblot analysis with antibodies against total and 
phosphorylated p53 at serine 20 and serine15. Cells were treated with 40µM BCNU as described 
in the Materials and Methods section and cells were collected at 12, 24, 48 and 72 hours post 
BCNU treatment, for immunoblot analysis. Whole cell lysate was probed with antibodies against 
total p53 and p53 phosphorylated at serine 20 or serine 15 (see Materials and Methods). Figure 
3.29 and Figure 3.30 shows the immunoblots and their quantified values respectively, for total 
and phosphorylated p53 (ser20) levels in sensitive and resistant cell lines in both the mock-
treated and BCNU treated samples. Figure 3.31 and Figure 3.32 show the same for 
phosphorylated p53 (ser15). There is a significant increase in total and phosphorylated p53 for 
the most sensitive cell line 4. The other cell lines also show a similar trend of p53 activation, but 
not with statistical significance.  
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Flow cytometry plots showing DNA content vs. Phopho-histone H3 for cell lines 4, 5, 13 and 16 at 48 
hours post BCNU treatment. The population representing mitotic cells is highlighted. 
Figure 3.27: Phospho-histone H3 at 48h post BCNU treatment 
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Sensitive cell lines show a significant drop in the mitotic population after BCNU treatment as compared 
to the resistant cell lines. 
Figure 3.28: Quantified mitotic fraction at multiple time-points post BCNU treatment 
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Figure 3.29: Immunoblots probed for phosphor-p53 (ser20) 
Immunoblots for BCNU and mock treated cells from cell lines 4, 5, 16 and 13 probed with antibodies 
against phosphorylayted p53 (ser 20), p53 and B-actin (loading control).  
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Quantitated data from immunoblot analysis of mock-treated and treated samples at 0, 12, 24, 48 and 
72hours post BCNU treatment for cell lines 4, 5, 16 and 13 using antibodies against total p53 and p53 
phosphorylated at Serine 20. All values were normalized to b-actin as a loading control and scaled to a 
positive IR control. 
Figure 3.30: Total and phosphorylated p53 (Serine 20) as measured by immunoblot for BCNU 
treated samples 
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Figure 3.31:  Immunoblots probed for phospho-p53 (ser15) 
Immunoblots for BCNU and mock treated cells from cell lines 4, 5, 16 and 13 probed with antibodies 
against phosphorylayted p53 (ser 15), p53 and B-actin (loading control).  
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Figure 3.32:  Total and phosphorylated p53 (Serine 15) as measured by immunoblot for BCNU 
treated samples 
Quantitated data from immunoblot analysis of mock-treated and treated samples at 0, 12, 24, 48 and 
72hours post BCNU treatment for cell lines 4, 5, 16 and 13 using antibodies against total p53 and p53 
phosphorylated at Serine 15. All values were normalized to b-actin as a loading control and scaled to a 
positive IR control. 
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Expression values of canonical p53 targets in cell lines 4, 5, 16 and 13 in mock-treated (blue) and treated 
(red) samples at 0, 4, 8, 12, 24, 36, 48 and 72hours post BCNU treatment from microarray measurements. 
Values are log2 ratios of the expression at each time point compared to the zero hour time point. 
Figure 3.33: Expression of canonical p53 targets from transcriptional profiles 
Chapter 3: Transcriptional Response to BCNU 
 
       
   
134 
To confirm p53 activation in the cell lines, we also looked at the gene expression of canonical 
p53 targets in the four cell lines from the microarray data set. Figure 3.33 shows induction of 
P21, GADD45A, XPC and DDB2, all known to be canonical targets of p53. Therefore, although 
only moderate p53 accumulation and phosphorylation was observed after BCNU treatment in the 
sensitive cell lines, this level of activation seems to be sufficient to activate expression of p53 
targets.  
 
3.4.15 Computational promoter sequence analysis shows that a subset of 
down-regulated genes are enriched for NF-Y binding motifs and 
predicted to be novel NF-Y targets 
 
We used the EXPANDER (9-12) package and its built-in transcription factor enrichment 
platform PRIMA to identify transcription factors with motif matchces that are enriched within 
the promoter regions (-1000 to 200bp region around the transcription start site) of either the up-
regulated or down-regulated genes (see Materials and Methods section). As shown in Figure 
3.34, the down-regulated genes showed significant enrichment for binding sites for four 
transcription factors- Nuclear Factor Y (NF-Y), Aryl Hydrocarbon Receptor (AhR), GA binding 
protein (GABP) and Nuclear respiratory factor 1 (Nrf-1). The genes whose promoter regions 
have binding motifs for these transcription factors are shown in Table 3.5, Table 3.6, Table 3.7 
and Table 3.8. On the other hand, within the -1000 to 200bp region around the transcription start 
site, there were no significant transcription factors identified for the up-regulated genes. 
 
To check whether the up-regulated genes contained transcription factor binding motifs outside of 
the -1000 to 200bp region, a larger range spanning the -3000 to 200bp region around the 
transcription start site (the maximum range allowed in EXPANDER) was searched for 
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transcription factor binding site enrichment. Table 3.9 shows the motifs enriched for various 
ranges of the promoter region analyzed. For the down-regulated genes, as the promoter range 
analyzed is increased, significance for enrichment is lost for Nrf-1 followed by GABP and 
finally AhR. The only motif enriched for all ranges tested is that of NF-Y, further increasing our 
confidence in the list of predicted NF-Y targets.  For the up-regulated genes, performing the 
enrichment analyses for the -2000 to 200bp region as well as the -2500 to 200bp region yields 
enrichment in the p53 binding motif. This enrichment is no longer significant when the region is 
increased to the -3000 to 200bp region, or decreased to the -1500 to 200bp region. Searching the 
-2500 to -1500 bp region of the promoters of the up-regulated genes alone does not yield 
significant enrichment for p53 binding motifs, therefore, the region between -1500 to 200bp 
around the transcription start site is required for the enrichment of p53 motifs. The list of genes 
containing the p53 binding motif is shown in Table 3.10.  
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The figure shows significance of enrichment for the binding sites of four transcription factors within the 
promoter regions (-1000 to 200bp region around the transcription start site) of the down-regulated genes 
(190). The percentage of genes in the down-regulated gene-set also enriched for the binding site of each 
transcription factor is shown on each bar. NF-Y (Nuclear Factor Y), AhR (Aryl Hydrocarbon Receptor), 
GABP (GA binding protein) and Nrf-1 (Nuclear respiratory factor 1). 
 
 
 
 
 
 
 
Figure 3.34: Transcription Factor Binding Site enrichment in the down-regulated cluster using 
EXPANDER 
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Genes highlighted in red are transcriptionally regulated by NF-Y and genes in blue have been shown to 
have NF-Y promoter occupancy (56,89-91).  
Table 3.5: Genes from the down-regulated gene set that are predicted to be NF-Y motif targets 
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Table 3.6: Genes from the down-regulated gene set that are enriched for the AhR motif 
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Table 3.7: Genes from the down-regulated gene set that are enriched for the GABP motif 
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Table 3.8: Genes from the down-regulated gene set that are enriched for the Nrf-1 motif 
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Table 3.9: Transcription factor binding motif enrichment for different promoter ranges for the up- 
and down-regulated genes 
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Table 3.10: Up-regulated genes containing p53 motifs in their promoter region 
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The role of NF-Y (most significantly enriched binding motif in the down-regulated genes) in the 
transcriptional DNA damage response was explored further. The set of predicted NF-Y targets 
consisted of 62 genes shown in Table 3.5, including three known NF-Y transcriptional targets 
CCNB1, CCNB2 and CCNA2. Although some of the 62 genes have been shown to have NF-Y 
promoter occupancy, a majority of the genes identified from our data set as having binding sites 
for NF-Y in their promoter regions are novel predicted NF-Y targets. 
 
The presence of bona-fide NF-Y targets CCNB1, CCNB2 and CCNA1 among the set of 62 
predicted targets improved our confidence in the set of predicted NF-Y targets. The known NF-Y 
targets contain an additional motif called the cell cycle homology region (CHR) within their 
promoter regions. Knowing that true NF-Y targets have a CHR motif within their promoter 
regions, we checked to see whether the novel predicted NF-Y targets had such a CHR motif in 
their promoter region as well. The promoter regions of the predicted NF-Y target genes (1000 bp 
upstream of the transcription start site) were scanned for the presence of the CHR motif. 53/62 
genes had both CHR and NF-Y motifs (p-value < 1x10-9, calculated using a hypergeometric 
distribution).  
 
3.4.16 Chromatin immunoprecipitation followed by sequencing (ChIP-seq) 
confirm NF-Y occupancy for novel predicted NF-Y targets 
 
To experimentally validate promoter occupancy of NF-Y for the computationally predicted, 
novel NF-Y targets, ChIP-seq was performed on log-growing cells from the most sensitive cell 
line 4. Briefly, cells were crosslinked in formaldehyde, and the chromatin was isolated, sonicated 
and immunoprecipitated with antibodies against NF-YA. The crosslinks were reversed and DNA 
was isolated and sequenced (see Materials and Methods). The sequencing results were analyzed 
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using Model-based Analysis of ChIP-Seq (MACS) (15) as described in the methods section. 
Together, the two separate sequencing runs yielded 17 million unique reads for chromatin from 
the NF-YA ChIP and 16 million unique reads from the control IgG ChIP. For a p-value cut-off of 
1X10-15, there were 3100 peaks called for the NF-YA ChIP as compared to the IgG control. At 
the same p-value cut-off, there were only 39 peaks called in the IgG control as compared to the 
NF-YA ChIP.  
 
Remarkably, of the 62 genes predicted as having NF-Y promoter occupancy, 54 were positive by 
ChIP-seq. 48 genes pass the stringent p-value cut off of p < 10-15. Three more genes pass a p-
value cut-off of p < 10-10 and an additional three pass a p-value cut-off of p<10-5. The remaining 
8 genes are negative for peaks (see Table 3.11). The four genes with the lowest p-value for peaks 
from the NF-Y ChIP are shown in the Figure 3.35. The four genes with the highest p-value for 
peaks from the NF-Y ChIP are shown in the Figure 3.36 and four genes with no significant peaks 
are show in Figure 3.37. The top 200 peak sequences were analyzed using the THEME algorithm 
(16) as a check to confirm that the peaks obtained are indeed from an NF-Y ChIP. As expected 
top motif enriched in this analysis was the NF-Y motif.  
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Table 3.11: Peaks called using MACS near the genes predicted to be NF-Y targets 
 
Genes predicted as NF-Y targets were examined for highly significant peaks. Genes are ordered based on 
their p-value, with white rows having high significance, and grey rows containing low-confidence or no 
peaks. Genes highlighted in red are transcriptionally regulated by NF-Y. Genes in blue have been shown 
to have NF-Y promoter occupancy. (56,89-91). 
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The figure shows peaks with the lowest p-value within the down-regulated genes obtained from the NF-Y 
ChIP-seq. For each gene, the top panel shows reads from the NF-Y IP and the bottom panel shows reads 
from the negative IgG control. The arrow indicates the direction of transcription 
Figure 3.35: Highly significant peaks from MACS analysis of NF-Y ChIP-seq data 
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The figure shows peaks with the highest p-value within the down-regulated genes obtained from the NF-
Y ChIP-seq. For each gene, the top panel shows reads from the NF-Y IP and the bottom panel shows 
reads from the negative IgG control. The arrow indicates the direction of transcription 
Figure 3.36: Weakly significant peaks from MACS analysis of NF-Y ChIP-seq data 
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Figure 3.37: Genes with no significant peaks from MACS analysis NF-Y ChIP-seq data 
The figure shows peaks with the highest p-value within the down-regulated genes obtained from the NF-
Y ChIP-seq. For each gene, the top panel shows reads from the NF-Y IP and the bottom panel shows 
reads from the negative IgG control. The arrow indicates the direction of transcription 
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3.4.17 Gene Set Enrichment Analysis (GSEA) shows enrichment of acetyl-
p53 repressed genes within the transcription signature 
 
p53 acetylation has been shown to be important for inhibition of NF-Y transcriptional activity. 
68 genes were identified as being repressed upon p53 acetylation at lysine 373 in (41). The 984 
probesets identified from our transcription data were analyzed for enrichment in p53 acetylation 
mediated gene repression using GSEA (see Materials and Methods). This analysis shows that the 
transcriptional signature is indeed enriched for genes repressed by p53 acetylation, with 14/68 
genes present within the transcriptional signature (FDR 0.3%). The enrichment plot is shown in 
Figure 3.38A with the enrichment score shown in green and the black lines showing the location 
of the 14 genes along the ranked list of genes within the transcriptional signature. 13/14 genes 
repressed after p53-acetylation were also repressed in sensitive cell lines after BCNU treatment 
as seen by the skewing of the black lines towards the blue region of the enrichment plot. Figure 
3.38B shows the 14 genes that are repressed after p53 acetylation and present within the 
transcriptional signature set. 11 out of these 14 genes have strong NF-Y promoter occupancy and 
are marked in Figure 3.38B. 
 
3.4.18 Immunoblot analysis shows no significant p53 acetylation in BCNU 
treated cells 
 
To check whether BCNU induced p53 acetylation at lysine 373 in the BCNU sensitive or 
resistant cell lines, cells were treated with 40µM BCNU and collected at 0, 12, 24, 48 and 72 
hours for immunoblot analysis with antibodies against total p53 and acetyl p53 (lysine 373) (see 
Materials and Methods). Figure 3.39 shows that the antibody used detects p53 acetylation 
induced by etoposide treatment in cell line 16. The immunoblots for cell lines 4, 5, 13 and 16 
treated with BCNU are shown in Figure 3.40 and the quantified values are shown in Figure 3.41. 
We see no significant differences in p53 acetylation between mock-treated and treated cell lines. 
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Genes repressed upon p53-acetylation (list of 68 obtained from (41)) were enriched in the 984 probe-sets 
(FDR 0.3%) in the transcriptional signature. A) Enrichment plot showing the position of the 14 of the 68 
genes –black lines- within the 984 probe-sets, ranked based on expression (red – high in sensitive cell 
lines, blue- low in sensitive cell lines). B) List showing these 14 genes and the promoter occupancy from 
NF-Y ChIP-seq (y – yes) 
  
 
Figure 3.38: GSEA of the transcriptional signature shows enrichment of genes repressed upon p53 
acetylation 
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Figure 3.39:Etoposide treated samples probed with the antibody against acetyl-p53 (lys373) 
(A) Immunoblots for cell lysate from cell line 16, treated with 50μM etoposide (see Materials and 
Methods) probed with antibodies against acetyl-p53 (lys 373), p53 and vinculin; (B) Barchart showing the 
average fold-change in acetyl-p53 (lys373) for etoposide treated samples over untreated samples. 
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Figure 3.40: Immunoblot probed for acetyl-p53 (lysine 373) 
Immunoblots for cell lines 4, 5, 16 and 13 at various time points after 40μM BCNU treatment 
probed with antibodies against acetyl-p53 (lys373), p53 and vinculin (loading control). Cell 
lysate from untreated, IR (10gy) treated and etoposide (50μM) treated samples from cell line 16 
were used as controls for each blot and for comparison across blots. 
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Acetylated p53 (top) and total p53 (bottom) levels in cell lines 4, 5, 16 and 13 in mock-treated and BCNU 
treated samples at multiple time-points. All values are normalized to the loading control vinculin and 
scaled to a positive IR control.. 
 
Figure 3.41: p53 acetylation as measured by immunoblot after BCNU treatment 
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3.5 Discussion 
 
The goals of this study were: i) to identify a transcriptional signature that cell lines that are 
resistant or sensitive to BCNU treatment; and ii) to find putative transcriptional regulators of this 
transcription signature. 
 
The wide range of BCNU sensitivity observed in the panel of twenty four genetically varied cell 
lines allowed the identification of cell lines with extreme BCNU sensitivity or resistance.  The 
706 genes identified as being differentially expressed between sensitive and resistant cell lines 
after BCNU treatment reveal interesting properties about the BCNU induced transcriptional 
differences between these cell lines. Genes within the transcriptional signature have visibly 
stronger gene induction or repression upon BCNU treatment in the sensitive cell lines as 
compared to the resistant cell lines. The muted transcriptional response in the resistant cell lines 
might suggest that the resistant cell lines induce DNA damage response pathways through 
mechanisms other than transcription. Additionally, since the ANOVA analysis enforced a 
differential gene expression signature between sensitive and resistant cell lines, it might also be 
the case that the transcripts induced or repressed in resistant cell lines are also induced and 
repressed to similar extents in the sensitive cell lines and therefore not included in the 
transcriptional signature. 
 
The transcriptional signature was partitioned into two sub-groups with different biological and 
functional annotation that correlated with cellular phenotype. We infer that two major and 
distinct processes are initiated in the BCNU treated sensitive cell lines. The first is the induction 
of apoptotic cell death as suggested by gene ontology enrichment of apoptosis within the up-
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regulated set, networks enriched in cell death related genes and the experimental observation of 
apoptotic cell death. The second process initiated in BCNU treated sensitive cell lines is the lack 
of entry into mitosis as suggested by gene ontology enrichment of the mitotic phase of the cell 
cycle within the down-regulated set, networks enriched in cell cycle related genes and 
experimental observation of a decreased mitotic population. Taken together, these results suggest 
either that the sensitive cell lines don’t reach mitosis or that they initiate a protective program 
that prevents the entry of cells into mitosis or even both. All of these stall proliferation of cells 
containing BCNU induced DNA damage. This also suggests that sensitive cell lines 
simultaneously initiate cell death mechanisms most likely to eliminate cells that are unable to 
repair the BCNU induced damage. 
   
The other observation from the transcriptional data set was the enrichment of the p53 signaling 
canonical pathway within the up-regulated set of genes using network building algorithms, 
which was also seen experimentally. Note that although the p53 signaling pathway was enriched 
only in the up-regulated gene set, p53 appears as a hub node in networks generated for both the 
up-regulated and down-regulated gene sets (Figure 3.23B and Figure 3.24B). This discrepancy 
arises from the definition of the canonical p53 signaling pathway that mostly include only those 
p53 targets that are transactivated as seen in Figure 3.23, but not those targets that are repressed 
or inhibited by p53 as seen in Figure 3.24.  Therefore, although p53-mediated repression 
interactions are included in the Ingenuity database and seen in Figure 3.24B, they have not been 
incorporated into the p53 canonical pathway.  
 
Chapter 3: Transcriptional Response to BCNU 
 
       
   
156 
In addition to this, there are other assumptions made in the use of such network analysis 
techniques. Using curated knowledge to understand the gene set of interest assumes that 
transcript levels correctly depict protein levels. This, however, is not necessarily true, and genes 
that seem to be induced at the transcript level might still be lacking at the protein level due to 
rapid degradation of the protein or poor translation of the transcript (42-44). The other 
assumption with these analysis techniques is the generality of the curated data. Certain reactions, 
interactions, induction and repression are often specific to the particular cell type or condition 
being studied while being irrelevant for the system under consideration. Moreover, the quality of 
interactions in the database might vary greatly depending on what experimental techniques were 
used to identify the interactions. Nevertheless, using known biological interactions can help us 
identify pathways that are possibly activated or repressed within our data set, and produce a 
better understanding of the meaning of our transcriptional signature in the context of DNA 
damage. For example, the network and functional analysis not only suggested a role for p53 in 
the BCNU induced transcriptional response but also suggested the induction of apoptosis and the 
absence of entry into mitosis, both of which were also seen experimentally. 
 
Significant binding site enrichment of the transcription factors NF-Y, AhR, GABP and Nrf-1 
within promoter regions of the down-regulated genes suggested that these transcription factors 
might control the expression of genes involved in mitosis. The fact that the NF-Y motif was 
enriched for all ranges of the promoter region tested improved our confidence in the predicted 
targets of NF-Y.  The only transcription factor binding site enrichment identified for the up-
regulated set of genes was that of p53. This is in concurrence with the induction of canonical p53 
targets (Figure 3.33) suggesting p53 transcriptional activation of a sub-set of up-regulated genes. 
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However, the lack of other significantly enriched transcription factor binding site enrichment 
within promoter regions of the up-regulated genes could be due to several reasons. One could be 
that the binding motifs might occur outside the search range possible in EXPANDER. Another 
reason could be that our knowledge of binding motifs for transcription factors is incomplete and 
so the motif enriched within the up-regulated set might still be unknown and absent in the 
TRANFAC data base that the motif-searching algorithm relies. Moreover, the set of up-regulated 
genes with the same expression patterns might be activated by different transcription factors, 
thus diluting out the enrichment for any one particular transcription factor within the set of up-
regulated genes.  
 
Further exploration of BCNU induced transcriptional repression of mitotic genes was pursued 
with the most significantly enriched transcription factor, NF-Y. The second most significant 
transcription factor, AHR was not explored because examination of its list of predicted targets 
did not include canonical AHR targets such as the CYP1 family of genes. Moreover, the 
transcription factor motif for AHR is often identified as a false positive in computational 
promoter sequence analyses (personal communication, Shao-shan Huang). Furthermore, 
literature review of the transcription factors suggested an interesting role for NF-Y in the control 
of mitotic genes after DNA damage. 
 
Nuclear Factor Y (NF-Y) is a trimeric complex composed of NF-YA, NF-YB and NF-YC (45, 
46). NF-Y has been shown to bind to promoter regions of, and transactivate multiple genes in a 
CCAAT motif dependent manner. The CCAAT motif is over-represented in promoter regions of 
the human genome, with ~30% of promoters containing this pentanucleotide sequence (47). In 
Chapter 3: Transcriptional Response to BCNU 
 
       
   
158 
line with this, NF-Y has been shown to bind and transactivate genes showing a wide range of 
expression patterns including ubiquitously expressed genes, cell cycle dependent genes and 
stress responsive genes (48-50). Moreover, NF-Y has been shown to recruit and increase binding 
affinity of other transcription factors at promoter regions (50-53). These facts suggest a complex 
and combinatorial regulation of NF-Y targets. Over the past decade, NF-Y has emerged as an 
important regulator of cell cycle progression, cell cycle checkpoints and chromatin remodeling 
under both non-stressed and DNA damage conditions (54-56). 
 
Bioinformatic analyses of promoter sequences have implicated NF-Y as a regulator of a large set 
of mitotic cell cycle genes due to the presence of the CCAAT motif in these promoter sequences 
(12,57). A few of these genes (CCNB1, CCNB2, CCNA2 and CDC25C) have been shown 
experimentally to be transcriptionally regulated by NF-Y (56). These known NF-Y mitotic 
targets have varied expression levels for different phases of the cell cycle, with low or no 
expression during G1, expression beginning during S-phase, with transcript levels accumulating 
all the way up to the end of G2. Such gene expression regulation is dependent on a motif present 
within the promoter regions of the mitotic genes, referred to as a cell cycle homology region 
(CHR) (58-61). In the absence of CHR elements in the promoter region, constitutive expression 
of mitotic genes has been observed (62,63). The exact mechanism of transcriptional repression of 
mitotic genes via the CHR motifs is not well understood, but thought to involve multi-protein 
complexes (64,65). The significant enrichment of the CHR motif within the promoter regions of 
the predicted NF-Y targets within our data set further improved our confidence in the predicted 
set of novel NF-Y targets, and suggested similar expression regulation for these new putative 
NF-Y targets. Moreover, significant promoter occupancy of NF-Y for 54 (p<10-5) of the 62 
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predicted target genes implies NF-Y regulation of these mitotic genes and a possible role for NF-
Y in a G2 arrest after BCNU treatment. 
 
Previous studies showed that human cells treated with BCNU induce a late S or G2/M arrest 
(28,40,66). However, the transcriptional control in the initiation of such an arrest after BCNU 
treatment has not been studied yet. G2/M arrest after DNA damage is thought to be initiated 
mainly through the regulation of CDK1 activity through multiple processes including an increase 
in its inhibitory phosphorylation by WEE1 (67-70), inhibition of its activating phosphatase 
CDC25C (71-73), exclusion from the nucleus and sequestration of its binding partner CCNB1 
(74,75). Additional transcriptional control of the G2/M arrest has been suggested by the p53 (76-
80) and E2F family of transcription factors (81-85). Few studies have also implicated NF-Y in 
DNA damage induced G2/M arrest.  
 
Protein levels of mitotic proteins such as CCNB1 and CDK1 drop during DNA damage induced 
G2/M arrest. This drop in protein level is partially attributed to protein degradation and partially 
attributed to transcriptional repression of the CCNB1 and CDK1 genes (76). These genes have 
CCAAT motifs in their promoter regions (84,86) and NF-Y has been shown to regulate 
expression from the promoters of these genes. NF-Y activity at the promoter regions of these 
mitotic genes is reduced upon DNA damage (54) thus explaining the decreased expression of 
CCNB1 and CDK1 during G2/M arrest after DNA damage. Moreover, cells lacking NF-YA or 
NF-YB show cell cycle defects, in particular the induction of a G2/M arrest with concomitant 
decrease in the expression of mitotic genes (55,87). This shows that NF-Y transcriptional control 
of cell cycle genes is important for proper control of G2/M both in the absence and presence of 
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DNA damage. In the context of these findings, our study adds to the list of mitotic genes with 
NF-Y promoter occupancy, that are most likely repressed during a G2/M arrest with the same 
mechanisms of repression seen for the key mitotic gene CCNB1. This also suggests a role for 
similar transcriptional control of a G2/M arrest in the sensitive cell lines after BCNU treatment. 
 
One mechanism proposed for transcriptional inactivation of the NF-Y after DNA damage is the 
inhibition of NF-Y by acetylated p53 (88). p53 has been shown to localize to promoter regions of 
mitotic genes especially after DNA damage (89). Biochemical analysis revealed that this occurs 
through the interactions of p53 with the NF-YC component of trimeric NF-Y. Mutational 
analysis identified that the C-terminal regions of p53 is required for the p53-NF-Y interaction 
(88). Moreover, p53 acetylation at the C-terminal region of p53 was shown to be important for 
the repression of NF-Y activity after DNA damage. In addition to this, p53 acetylation alone was 
shown to induce transcriptional changes and G2/M arrest (41). The enrichment within our 
transcriptional signature (especially in the down-regulated set) for genes that are repressed by 
p53 acetylation suggested a similar mechanism of transcriptional control for the set of down-
regulated mitotic genes. However, immunoblot analysis showed a lack of p53 acetylation after 
BCNU treatment in cell lines 4 and 16. This outcome could result from one of many possible 
reasons. One possibility is that p53 is not acetylated in these cell lines after BCNU treatment, at 
least at the site probed (lysine 373). In this case, it could be that lymphoblastoid cell lines used in 
this study employ mechanisms other than p53 acetylation for the repression of NF-Y bound 
mitotic genes. Another possibility is that the amounts of acetylated p53 might be too low to be 
detected using the technique we used. It could also be that acetylation might be occurring at 
lysines other than the site probed that might also be able to inhibit NF-Y. Therefore, we were 
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unable to prove or disprove the role of p53 acetylation in mediating the repression of NF-Y 
mitotic targets after DNA damage.  
 
Taken together, our results suggest transcriptional control of the observed G2 arrest in the BCNU 
treated sensitive cell lines by NF-Y possibly mediated by p53 acetylation or some as yet 
unknown mechanism as shown in Figure 3.42. The model suggests that under normal cell cycle 
progression, NF-Y transcriptionally regulates a large panel of mitotic genes. In the presence of 
DNA damage, the transcriptional activity of NF-Y on this panel of mitotic genes is inhibited, 
possibly by acetylated p53 or some other novel mechanism. This model also suggests a possible 
link between DNA damage signaling and control of cell cycle thus facilitating constant 
monitoring of the presence of damaged DNA. 
 
To conclude, we identified a transcriptional signature of genes differentially expressed between 
sensitive and resistant cell lines after BCNU treatment that was informative of two major and 
distinct processes initiated by sensitive cell lines after BCNU treatment – the stalling of entry 
into mitosis and the initiation of cell death by apoptosis. Furthermore, we identified NF-Y as a 
possible regulator of BCNU induced G2/M arrest and also identified novel NF-Y targets that are 
part of the transcriptional response for a G2 arrest after BCNU treatment. Finally, the lack of p53 
acetylation in the cell lines used here suggests that these cell lines might use mechanism other 
than the known mechanism of p53 acetylation for the repression of NF-Y mitotic target genes 
after BCNU treatment.  
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Figure 3.42: Model for repression of NF-Y mitotic targets mediated by p53 acetylation 
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There are a few key ideas that provided the vision for, and formed the core of this thesis. The 
first idea was the use of computational and systems biology techniques to study the complex 
biological components of the transcriptional response of human cells to DNA damaging agents. 
The design of the experimental system and the choice of the measurement techniques were key 
decisions that allowed the generation of a multi-dimensional and information-rich data set 
amenable to computational analyses. Moreover, the use of computational tools enabled us to 
identify a biologically meaningful transcriptional signature and further to propose a mechanism 
for the transcriptional control of a subset of that signature, both of which would be difficult to 
identify otherwise. The interweaving of experimental and computational techniques that 
enhanced and complemented one another was an essential part of this project. The experimental 
and computational techniques chosen at each point of the project were motivated by the 
biologically relevant question at that step (see Figure 4.1) and yielded more insight into the 
transcriptional response to DNA damaging agents. For example, once the transcriptional 
signature was identified, bioinformatics analysis was used to determine the functions enriched 
within the gene set, which in turn led to the experimental measurement of cell death and mitosis 
in the cell lines. Similarly, computational identification of NF-Y as the transcription factor 
possibly regulating the mitotic genes led to the experimental measurement of NF-Y promoter 
occupancy for these genes.  
 
Another important idea that was explored in this thesis was the identification of a common 
signature for cell death/survival after exposure to a DNA damaging agent. Identifying genes with 
similar expression patterns in two separate cell lines (although in this case they were both 
lymphoblastoid cell lines) allowed us to exclude transcriptional changes that were specific only 
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to one particular cell line and not essential for BCNU sensitivity; this would not have been 
possible if only one sensitive or one resistant cell line were compared. Therefore, this project 
suggests that such common signatures specific for cell death could be identified. A crucial next 
step is to use a similar approach to identify transcriptional signatures for cell death across 
different DNA damaging agents. 
 
The third important point in this thesis was the power of using an exploratory approach. Many of 
the genes that fall within the transcriptional signature have not been previously identified as 
affecting sensitivity to DNA damaging agents. Therefore, if we had performed this same study 
with preselected sets of genes or transcription factors, we would have missed the identification of 
the signature. Moreover, without the signature gene set, we would not have identified the 
transcription factor NF-Y as playing a role in DNA damage response.  
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The experimental (red solid boxes) and computational (blue solid boxes) techniques used within this 
thesis are shown. The biologically relevant question that motivated these techniques are highlighted in 
black open boxes 
 
Figure 4.1: Experimental and computational techniques driven by biologically motivated questions
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The ideas, design and techniques implemented in this thesis yielded some important scientific 
contributions. The multi-well proliferation assay developed as part of this thesis is an efficient 
way to perform large scale screens to measure effects on proliferation of various types of drugs 
and treatments. Using this assay, high resolution measurements of survival can be obtained even 
for usually hard-to measure suspension cell lines. The assay enabled the otherwise impractical 
measurement of survival curves for the panel of 24 genetically diverse lymphoblastoid cell lines 
(grown in suspension) to BCNU sensitivity.  More importantly, the technique has potential for 
use in a wide variety of projects, with a wide variety of cell lines and chemicals or toxic agents. 
In the second part of the thesis, the transcriptional response after BCNU treatment in sensitive 
resistant cell lines was explored. This led to the identification of a transcriptional signature that 
suggested the activation of two important processes in the sensitive, BCNU treated cell lines; the 
induction of apoptosis and the stalling of entry into mitosis. Furthermore, the transcription 
signature correlated well with the observed cell phenotype which showed that these two 
processes were indeed occurring in the BCNU sensitive cell lines. This gene set was important in 
understanding the processes initiated in the sensitive cell lines after exposure to BCNU. Whether 
these genes behave similarly in response to other DNA damaging agents is not yet known and 
might be interesting to study.  
 
From the transcriptional signature, NF-Y was identified as an important regulator for the 
transcriptional control of genes involved in the mitotic phase of the cell cycle after BCNU 
induced DNA damage. Although NF-Y has previously been implicated in the transcriptional 
repression of a few G2 genes, it had neither been observed in response to BCNU, nor to the 
extent observed here. Moreover, BCNU has been shown to induce a G2/M arrest in glioblastoma 
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cell lines, but the transcriptional control of mitotic entry and the role of NF-Y in such an arrest 
have not been previously identified. NF-Y mediated repression of a few mitotic genes has been 
observed in multiple cell lines treated with different types of DNA damaging agents. This 
suggests that the control of G2 arrest by NF-Y could potentially be a general mechanism used by 
cells after DNA damage.  
 
The control of the G2/M checkpoint is important in the treatment of tumors since many of the 
DNA damaging agents used in the clinic induce a G2/M arrest. This arrest is thought to act as a 
protective mechanism, allowing time for the tumor cells to repair damage. Our results suggest 
that NF-Y could play an important role in the protective mechanisms employed by tumors 
against chemotherapy. However, our results also showed that the induction of apoptotic genes 
can overshadow the protective effects of a G2 arrest since the G2 arrest we observed in our 
sensitive cell lines did not ultimately protect them from BCNU induced cell death. Moreover, 
there was no G2 arrest observed in the resistant cell lines confirming that a G2 arrest is not 
required for resistance to DNA damaging agents and that other mechanisms such as induction of 
DNA repair proteins could also confer resistance, as has been seen in the clinic. These results 
suggest to some extent, an ordering of the effects of DNA repair, induction of apoptosis and cell 
cycle arrest on the cells’ survival after exposure to DNA damaging agents. These ideas could be 
exploited for use in combination therapy in the clinic, where multiple effective strategies such as 
inhibition of repair and cell cycle arrest and acceleration of apoptosis might sensitize some 
resistant tumors.  
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To this end, understanding the mechanism of NF-Y mediated repression in the control of the 
G2/M arrest after DNA damage could provide possible avenues for enhanced or more efficient 
chemotherapy. p53 acetylation has been suggested as a possible mechanism that controls the 
repression of NF-Y targets after DNA damage. However, the lack of p53 acetylation observed in 
the sensitive cell line after BCNU exposure could suggest that alternate mechanisms are more 
important for NF-Y repression in these lymphoblastoid cell lines than what has been studied so 
far. Other mechanisms for NF-Y regulation have also been suggested, including post-
translational modification of NF-Y and changes in chromatin structure. It would be interesting to 
explore which, if any, of these mechanisms are responsible for the observed NF-Y repression 
seen in BCNU treated cells. Interactions of NF-Y with varying partners and protein complexes 
have also been suggested as a method for the transcriptional control of NF-Y target genes. The 
identity of these interacting partners and protein complexes both in the absence and presence of 
DNA damage could also shed some light on other mechanisms of NF-Y mediated transcriptional 
control.  
 
As a result of this thesis, experimental and computational techniques suitable for extracting 
general gene signatures for cell death/survival after DNA damage were identified. The next step 
would be to apply these techniques to other DNA damaging agents to determine whether a drug 
independent signature for cell death can extracted using this technique. Such as study would, for 
example, reveal whether the G2 arrest controlled by NF-Y in BCNU treated cells is activated or 
important in the response to other chemotherapeutic agents. Preliminary results for the sensitivity 
of the BCNU sensitive/resistant cell lines to other DNA damaging agents used in the clinic are 
shown in Figure 2.  The results show that the cell lines have different sensitivities to 
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Temozolomide, but not to cisplatin and ionizing radiation. However, it is yet remains to be seen 
whether the panel of twenty four cell lines will indeed show a range of sensitivities to IR and 
cisplatin, and whether a G2 arrest is induced in treated cells.  
 
If NF-Y dependent transcription is observed in cell lines after treatment with the other DNA 
damaging agents, this would be an important step forward in understanding the common 
mechanisms for cell death/survival after DNA damage. The presence of such a common 
signature that is not dependent on the DNA damaging agent, and is unaffected by genetic 
variation across a population, would have the potential to improve current modes of 
chemotherapy by sensitizing treatment resistant tumors or by protecting sensitive non-tumor 
cells.  
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Survival curves for cell lines 4 (blue), 5 (green), 13 (red) and 16 (yellow), when treated with ionizing 
radiation (IR), BCNU, Cisplatin and Temozolomide as measured using the proliferation assay.  
Figure 4.2: Survival curves for cell lines 4, 5, 13 and 16 for four clinically used cancer treatments
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Appendix A:  
 
Genomic Predictors of Interindividual 
Differences in Response to DNA Damaging 
Agents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contribution: Partial Least Squares Regression analysis and statistical analyses for significance 
of the identified gene set. 
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Appendix B: 
 
Activation of Inflammation/NF-κb Signaling 
in Infants Born to Arsenic-exposed Mothers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contributions: Statistical prediction and significance analysis
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